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INTRODUCTION 
 
Diabetes Mellitus (DM) is a metabolic disease of carbohydrate 
metabolism resulting in hyperglycemia mainly due to absolute or relative 
deficiency of insulin secretion and or its action. As the global effect of 
Diabetes constantly intensifies, there is a need for intervention to slow 
down the progression of disease and to achieve metabolic control. 
 
Epidemiology 
           According to World Health Organisation (WHO), approximately 
250 million people currently have diabetes worldwide and this number will 
reach 380 million by the year 2030.  
 India is being termed the“ Diabetes capital of the world”. In India, 
approximately   40 million people are found to have diabetes and this will 
reach 70 million by the year 2030
1
. 
Diabetic Nephropathy (DN) is one of the chronic complication of 
Diabetes Mellitus(DM). Diabetic Nephropathy is identified clinically at the 
earliest by micro-albuminuria. 
 End Stage Renal Disease (ESRD), a devastating disease is mainly 
due to Diabetic Nephropathy and is the major cause for Diabetes related 
morbidity and mortality
2
. Around 10 – 20% mortality in diabetes is due to 
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renal failure. Chronic kidney disease due to Diabetic Nephropathy finally 
leads onto Renal Replacement Therapy
3
. 
 Diabetics have 17 fold higher mortality rate due to kidney disease 
than the persons without   Diabetes
4
. Vitamin D is the factor having an 
impact in the differential development of DN, as it posseses anti -
proliferative effect in cellular differentiation, immune modulation and 
inhibition of the renin - angiotensin system (RAS)
5
, apart from its role in 
maintaining bone homeostasis.   
Kidney disease might progress depending upon Vitamin D 
insufficiency versus deficiency
6
. Vitamin D metabolite, i.e., 1,25(OH)2 
vitamin D inhibited by the RAS has been established in vitro to emphasise 
its protective role in DN
7
. 
Rat studies are based on these demonstrations which showed that the 
administration of 1,25(OH)2D  helps in reducing the progression of 
glomerulo-sclerosis and albuminuria through mechanisms that are not 
dependent on parathormone functions and by its antiproliferative actions 
which finally also reduce podocyte hypertrophy and its loss
8,9
.These 
changes might be particularly applicable in individuals with Diabetic 
Nephropathy . 
When adequate vitamin D levels are maintained, there is an 
increase in the secretion of insulin by the β cells of pancreas and also there 
is a decrease in insulin resistance and arterial pressure. The potentially 
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modifiable factor, arterial blood pressure for diabetic nephropathy is said to 
decrease when there is a decrease in insulin resistance and also by an 
increase in the secretion of insulin, which are done by adequate vitamin D 
levels
10
.   
The role of vitamin D level to decrease insulin resistance and 
thereby to   decrease the formation of overt hyperglycemia needs to be 
analysed in our population. 
Only a very few human have dealt about the relationship between 
serum vitamin D levels and DN.  If the levels of vitamin D are adequately 
maintained whether it could prevent diabetic nephropathy needs to be 
studied.  
This study is to evaluate the serum 25-hydroxyvitamin D levels in 
Type 2 Diabetes Mellitus patients with and without nephropathy. 
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AIM  AND OBJECTIVES OF THE STUDY 
 
1. To assess the levels of serum 25-hydroxy vitamin D in patients  with  
 Type 2 Diabetes Mellitus with and without Diabetic Nephropathy. 
 
2. To correlate the levels of serum 25- hydroxy vitamin D, with urine     
microalbumin and serum creatinine   in patients  with  Diabetic  
Nephropathy. 
 
3. To assess the role of  vitamin D insufficiency Versus vitamin D 
deficiency in facilitating  the progression of Diabetic Nephropathy. 
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REVIEW OF LITERATURE 
DIABETES MELLITUS 
  The most commonly prevalent endocrine disorder is Diabetes 
Mellitus (DM). More than 170 million people were found to be affected 
world wide. Around 365 million people would be involved with this 
disease by  the year 2030
11
.   
Type 2 Diabetes Mellitus is expeditiously blooming as one of the 
greatest world wide health burden of the 21st century. The complications 
of diabetes mellitus like coronary artery disease, nephropathy, neuropathy, 
stroke and retinopathy
12
 which are the resultant of micro and 
macrovascular changes are also said to rapidly increase and thereby 
causing profound morbidity and mortality  in these group of patients. 
Hence diabetes mellitus can be aptly termed as global endocrine epidemic 
which needs urgent attention for prevention.  
        The major devastating complication of Diabetes is Diabetic 
Nephropathy, which leads on to End Stage Renal Disease (ESRD).   
Micro-albuminuria is a characteristic and early marker of DN. 
       Diabetes Mellitus, the most common metabolic disorder is 
characterised by chronic hyperglycemia associated with disturbance in the 
metabolism of carbohydrate, aminoacid and lipid metabolism due to, either 
absolute or relative deficiency of the secretion /action of insulin
13
. 
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 Diabetes Mellitus apart from being a metabolic disorder is also a 
multisystem disorder involving every vital organ of the body. Most 
importantly the involvement of heart and kidneys result in life threatening 
complications. 
TYPES OF DIABETES MELLITUS
14
: 
1. Type 1 Diabetes Mellitus occurs due to destruction of the β cells of 
pancreas  
Destruction of the β cells of pancreas is mainly due to : 
a) Autoimmune cause 
b) Idiopathic cause 
2. Type 2 Diabetes Mellitus 
Causes   are : 
a)  Resistance to insulin in the insulin target tissues. 
b)  Defects in insulin secretion by the β cells of pancreas. 
3. OTHER SPECIFIC TYPES OF DIABETES: 
a) Genetic defects in β cell dysfunction eg: MODY 1 to 11 
b) Genetic defects in insulin action eg: Type A insulin resistance 
c)  Pancreatic disease eg : fibrocalculus pancreatopathy 
d) Endocrine diseases eg:, Cushings disease, Acromegaly 
7 
 
e) Drugs  and chemicals induced eg : steroids 
f) Infections due to congenital rubella 
g) Rare disease of immune related diabetes eg: stiff man syndrome 
h) Other genetic disorders like Down’s syndrome 
4. GESTATIONAL DIABETES occurs during pregnancy which may 
either get corrected after parturition or result in DM (Type 2) accordingly. 
PATHOGENESIS OF DIABETES MELLITUS 
Characteristic features of Type 2 Diabetes Mellitus is mainly due to the 
following metabolic defects
15      
1. inadequate insulin secretion due to β-cell dysfunction.  
 2. decreased ability of peripheral  target tissues to respond to insulin   
     (insulin resistance).  
 Insulin resistance is the initial event in most cases, followed by 
increasing degrees of dysfunction of  the β-cells of pancreas . 
Physiology of the insulin secretion 
Glucose enters the β-cells of pancreas rapidly, through the glucose 
transporter 2 (GLUT2). Glucose phosphorylated by glucokinase, is one of 
the rate limiting steps of glycolysis. Several intermediates are formed and 
finally, leads to the formation of pyruvate.  
In the mitochondria, pyruvate is taken up to be involved in the Tri-
Carboxylic Acid (TCA) cycle in which the various intermediates permit 
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production of energy at substrate level as well as the relevant co-enzymes 
accepting the reducing equivalents (NADH, FADH2) to access the Electron 
Transport Chain (ETC), situated on the inner surface of the inner 
mitochondrial membrane and produce ATP, the currency of energy.           
  ATP is the essential energy needed for the insulin release as well as 
the depolarisation of the cell membrane. The adjacent potassium channel 
(potassium inward rectifier [KIR] 6·2 channel) is closed, when sulphonyl 
urea receptor 1 (SUR1) protein is stimulated by ADP/ATP ratio. This 
closure of   potassium channels causes a change in the membrane potential 
and thereby leading to opening of calcium channels and finally there is a 
release of preformed insulin containing granules
16
. 
Role of chromium on insulin action 
Chromium enhances the number of insulin receptors on the cell 
membrane and increases the insulin binding to the insulin target cells. It 
also stimulates insulin receptor kinase, resulting in increased insulin 
sensitivity
17
. 
 Pancreatic dysfunction of the β cell. 
In the initial course of Type 2 Diabetes Mellitus, Insulin secretion 
appears to be normal. However, normal   pattern of insulin secretion is lost 
and the first rapid phase in the secretion of insulin, stimulated  by glucose 
is decreased. It shows the derangement in the response of the β cells of the 
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pancreas to hyperglycemia. Finally, irreversible β cell damage occurs due 
to toxicity of glucose and lipid. 
Glucose toxicity 
Metabolism of glucose propagates the formation of Reactive Oxygen 
Species (ROS), in the β cells of pancreas. ROS require superoxide 
dismutase, catalase, and glutathione peroxidise, for detoxification, which 
are present in low amounts in the β cells of pancreas18. 
Hyperglycaemia enhances the accumulation of large amounts of 
ROS in the β cells of pancreas, with consequent damage to the components 
of the cell by increasing the NFκB activity, which stimulates the apoptosis 
of the β cell of pancreas.     
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The above flow chart depicts the formation of Reactive Oxygen 
species through several metabolic   pathways of glucose  metabolism.       
Lipotoxicity 
 Oxidation of fatty acid in the β cells of pancreas, is inhibited in the 
presence of glucose, resulting in the formation of long chain acyl 
coenzyme A
19
,
 
which in turn decrease the insulin secretory pathway, by 
opening the K
+
 channel of the β cells of pancreas.  
 Increased expression of uncoupling protein-2 due to accumulation of 
acyl coA decreases ATP formation. Insulin secretion will be inadequate 
in the absence of ATP. 
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 Higher fatty acyl-CoA levels within the β cell of pancreas enhance the    
synthesis of ceramide, which increases inducible nitric-oxide synthase
20
 
and the subsequent rise in nitric oxide stimulates the expression of 
Interleukin-1(IL-1) and Tumour Necrosis Factor alpha(TNF-α)which 
are the inflammatory cytokines, that affects the function of the  β-cells 
of pancreas, promoting apoptosis of the β-cells of pancreas21. 
Insulin resistance 
Insulin secreted by the β-cells of the pancreas, is the anabolic 
hormone, its action is necessary for the homeostasis of glucose, fat and 
protein metabolism
22
. 
Insulin resistance
23 
  is defined as the incapability of insulin target 
tissues, such as skeletal muscle and adipose tissue, to respond effectively to 
the insulin secretion. 
Insulin resistance might be due to reduction in the number of insulin 
receptors or diminution in the post receptor signalling of insulin receptors 
with or without deterioration in the number of insulin receptors. 
Mechanism of insulin resistance 
i)  Role of Phosphorylation and De-phosphorylation of Insulin 
Receptor Substrate (IRS). 
  The insulin receptor (IR) is a hetero-tetramer has α and β subunits, 
two each, are linked by disulphide bonds. Insulin binds to the α subunit of 
the insulin receptor and  stimulates the tyrosine kinase in the β subunit.  
12 
 
Once the tyrosine kinase is activated, it favours the auto-
phosphorylation of the β subunit, i.e., phosphorylation of three tyrosine 
residues(Tyr-1163, Tyr-1162, and Tyr-1158)
24
. Two major cascades such 
as mitogen-activated protein (MAP) kinase pathways and  phospho-
inositide 3-kinase (PI3K) are triggered, which mediate the growth-
promoting and metabolic functions of insulin
25 
 .  
By reducing tyrosine phosphorylation while enhancing serine and 
threonine phosphorylation of the insulin receptor, insulin resistance is 
exacerbated that has an blocking effect on insulin signaling
26
. 
Phosphotyrosine phosphatase1B is expressed widely and  has an 
opposite effect in insulin signaling
27
. 
ii) Role of adipocyte and inflammation 
In normal individuals, insulin impedes  lipolysis by inhibiting 
Hormone Sensitive Lipase(HSL). In Insulin resistance, lipolysis is 
increased with an increase in circulating Free Fatty Acid (FFA); Hence in 
obesity, mainly increased adipocity in the visceral area, are of great 
relevance. 
Increased Non Esterified Fatty Acid (NEFA),TNFα and IL-6 released by 
visceral adipose tissue untowardly affect the insulin signalling cascade
28
. 
 Glucose metabolism in skeletal muscle stimulated by insulin is 
inhibited by NEFA and gluconeogenesis is triggered by NEFA in liver
29
. 
NEFA stimulate cellular kinases, such as isoforms of atypical protein 
13 
 
kinase C by enhancing cellular diacylglycerol levels, which in turn can 
stimulate the c-jun N-terminal kinase and inflammatory kinases inhibitor k 
B kinase (IKK), enhancing serine/threonine phosphorylation of insulin 
receptor resulting in decreased insulin signaling
30,31
. 
   TNFα stimulates lipolysis in adipocytes, then stimulate NEFA, and 
exerts direct inhibitory action on insulin signalling cascade
32
.  
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Diabetic Nephropathy (DN) 
 
The major microvascular complication of Diabetes Mellitus is DN. 
Diabetic Nephropathy was identified by Clifford Wilson and Paul 
Kimmelstiel
33 
in 1936. 
Other names of Diabetic Nephropathy are 
 Kimmelstiel -Wilson syndrome or  
 Nodular diabetic glomerulo- sclerosis or  
 Inter-capillary glomerulo-nephritis,  
Diagnostic features of DN are 
i. Albuminuria (>300 mg/day or >200 µg/min), 
ii.  Permanent and irreversible diminution of Glomerular 
Filtration Rate (GFR) 
iii.  Elevated blood pressure. 
Diabetic Nephropathy is a progressive disorder and is associated 
with high morbidity and mortality rates. Normally, no albumin is excreted. 
But, the initial step in Diabetic Nephropathy is the progression from 
normo- albuminuria to micro- albuminuria, which progresses to macro 
albuminuria, affecting the renal function by deteriorating the GFR 
34
. 
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Albuminuria could be due to structural abnormalities, mainly   
glomerular in origin
35
 presenting with : 
i. increased pressure in the glomerulus,  
ii. loss of negatively charged glycosaminoglycans in the glomerular 
basement membrane   
iii. the enlargement of the pore size of the basement membrane.  
Multi-factorial risk factors for Diabetic Nephropathy are : 
i. Hyper-glycemia, 
ii. Hypertension, 
iii. Genetic factors,  
iv. Obesity, 
v. Sedentary lifestyle, 
vi. Advancing age
36
, 
vii. Smoking. 
Stages of Diabetic Nephropathy 
37
 
Diabetic Nephropathy can be classified into different clinical stages based 
on 
i. GFR 
ii. Systemic Blood Pressure  
iii. Urinary albumin excretion rate (UAER). 
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STAGES OF DIABETIC NEPHROPATHY 
 
 
 
 
 
 
 
STAGES 
 
DESIGNATION  
 
URINE ALBUMIN 
 
EXCRETION(UAE) 
 
   GFR 
 
BLOOD 
PRESSURE 
 
STRUCTURAL 
CHANGE 
 
 
 
I 
 
Hyperfunction/ 
 
Hypertrophy 
 
 
May be increased 
 
 
Maybe 
increased 
 
Usually 
normal 
 
Glomerular  
 
hypertrophy 
 
 
 
 
 
II 
 
 
Normo-
albuminuria 
 
Normal albumin loss 
(UAE excretion <30 
mg/24h) 
 
 
 
 
Normal/ 
Increased 
 
 
Usually 
normal 
 
 
 
Increasing 
basement 
membrane 
thickening & 
mesangium 
expansion 
 
 
 
 
III 
 
 
Incipient diabetic 
nephropathy 
 
Microalbuminuria 
(UAE excretion 
30–299 mg/24h) 
 
 
 
Normal/ 
Increased 
 
 
Increasing  
 
IV 
 
Overt  diabetic 
nephropathy 
 
 
 
Macroalbuminuria 
(UAE excretion 
≥300 mg/24h) 
 
 
 
Decreasing  
 
 
Hypertension 
 
 
 
Increasing 
glomerular 
occlusion and 
severe mesangial 
expansion 
 
 
 
 
V 
 
 
 
 
End stage kidney 
disease 
 
 
Macroalbuminuria 
often decreasing 
because of 
glomerular occlusion 
 
 
 
 
 
 
<20 
ml/min 
 
 
 
 
Frank 
Hypertension 
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PATHOGENESIS 
Several mechanisms plays an important role in the development   of   
Diabetic Nephropathy,  due to the relationship between  
 
i. Hemodynamic pathways, 
 
ii. Hyperglycemia induced metabolic pathways  
 
iii. Inflammatory pathways. 
 
 
i. HEMODYNAMIC PATHWAYS 
 
Both the afferent and efferent arterioles of the glomerulus having reduced 
resistance is the earliest sign. This results in glomerular hyper-filtration and 
hyper-perfusion. 
 
Many factors are responsible for this defective auto-regulation, 
including 
i. Prostanoids,   
ii. Nitric oxide(NO) 
iii. Vascular endothelial growth factor (VEGF),  
iv. TGF-β1   
v. Renin Angiotensin System (RAS). 
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The early hemodynamic changes contribute  
 
1. Facilitate the oozing of albumin from the glomerular capillaries,  
 
2. Increased production of matrix of mesangial cell,  
 
3. Glomerular basement membrane thickening,  
 
4. Podocytes injury
38
,  
 
5. Release of growth factors and certain cytokines
 39
.  
 
 
The above flow chart depicts the interaction of hemodynamic and 
metabolic pathways in Diabetic Nephropathy. 
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ii. THE EFFECT OF HYPERGLYCEMIA ON METABOLIC   
 PATHWAYS: 
 
Hyperglycemia is a primodial factor in the formation of DN, 
exerting   harmful changes in  the glomerular basement membrane and 
mesangial cells. It initiates a main role in the development of DN by 
interacting with the metabolic and hemodynamic factors. 
        Mesangial cells are responsible for the maintenance of the structure 
of glomerular capillary, and through smooth-muscle activity,mesangial 
cells alters the glomerular filtration rate. 
       Hyperglycemia results in increased proliferation and hypertrophy of 
mesangial cells
40 
in addition, there is increased production of mesangial 
matrix and thickening of glomerular basement membrane.  
Mechanisms   causing tissue damage due to hyperglycemia are :  
 
1. Non-enzymatic glycosylation that produces Advanced Glycosylation  
 
End products (AGE) 
 
2. Protein Kinase C(PKC) activation  
3. Activation of the aldose reductase pathway
41
 
4. Increased Hexosamine pathway. 
 Oxidative stress is the common theme to all these pathways
42
. 
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The above flow chart depicts the various interactions between metabolic 
pathways in diabetic nephropathy. 
 
a)  Increased AGE(Advanced Glycation End products) 
 
Tissue protein glycosylation results in the formation of DN and other 
microvascular complications. In chronic hyperglycemia, the increased 
glucose binds non-enzymatically with tissue proteins or free amino acids to 
form reversible glycated proteins.In the early stage,these reversible 
glycated products affect the  basement membrane of the glomerulus and 
mesangial matrix components.  
21 
 
By modulating signal transduction through the alteration in the level 
of signals, such as, free radicals, cytokines and hormones, progressive 
glycation forms irreversible AGEs, amenable for the pathogenesis of 
Diabetic Nephropathy, 
The accumulation of AGEs in the tissue enhances cross linking with 
collagen and extracellular matrix proteins, which contribute to renal and 
micro-vascular complications
43
.    
  AGEs accelerate atherosclerosis, promote glomerular dysfunction, 
decrease NO  synthesis and induce endothelial dysfunction. Finally, there 
is an alteration in extracellular matrix composition and structure. 
 
b) Activation of Protein kinase C (PKC) 
 
a) De novo formation of Diacylglycerol(DAG) resulting in PKC 
activation and oxidative stress
44
 is mainly due to hyperglycemia.  
b) PKC activation is responsible for the increased secretion of 
prostanoids resulting in glomerular hyperfiltration
45
. 
c)  PKC increases the production of extracellular matrix in 
mesangial cells
46 
by activating TGF-β1. 
d) The activation of PKC stimulates the MAPKs activity, through 
dual phosphorylation at conserved tyrosine and threonine 
residues,triggered by extracellular stimuli such as hyperglycemia. 
The co-activation of MAPK and PKC in the presence of 
22 
 
increased   glucose concentration   suggests the interlink of the 
two families of enzymes
47
. 
e) PKC modulates the transcription of gene for collagen Type IV, 
fibronectin, extracellular matrix proteins and contractile proteins, 
in neurons and endothelial cells.    
 
 
C)  Increased polyol pathway 
.  
Hyperglycemia increases the glucose metabolism via sorbitol 
pathway. Glucose is converted to sorbitol by the enzyme aldose reductase 
when the intracellular glucose is elevated.  
Several mechanisms explain about the polyol pathways.
48
 
 Sorbitol induces osmotic stress 
 Decreases cytosolic Na2+ / K+ ATP ase activity 
 Reduces cytosolic NADPH, which in turn increases oxidative stress 
in the cell 
 Increase in the cytosolic ratio of NADH/NAD+ 
The surge of the NADH causes inhibition of glyceraldehyde 3-
phosphate dehydrogenase which causes an increase in concentration of 
triose phosphate
49
 which could increase the formation of methyl glyoxal, 
which is a highly active glycating compound and methyl glyoxal  is a 
precursor of AGEs and via α-glycerol -3-phosphate, increase the 
production of diacyl glycerol which activates protein kinase C. This 
23 
 
pathway is normally inactive and gets activated only when intracellular 
glucose level starts elevating. 
 
d)  Increased hexosamine pathway 
Glucosamines formed from excess glucose,in hexosamine pathway 
could be one of the reason for  the development of diabetic complications.  
All these culminate in the process of DN such as activation of protein 
kinaseC, increased TGF-β expression and extracellular matrix 
production
50
.Rise in TGF-β expression in the kidney stimulated by 
glucose,structural alterations in kidney
51
 due to glucosamine  has been 
demonstrated in the experimental animals. TGF-β exerts a main role in the 
development of Diabetic Nephropathy
52
 due to the interaction with the 
RAS and PKC activity. 
 
iii) INFLAMMATORY PATHWAY 
 
 
Proteinuria, a diagnostic factor in DN, is significantly associated 
with inflammation, as it induces the renal tubular cell activation, resulting 
in the expression of pro-inflammatory cytokines, adhesion molecules and 
numerous chemokines. Consequently, these responses culminate in 
infiltration  of interstitium by lymphocytes, monocytes, macrophages and  
24 
 
neutrophils, which then results in renal cell damage, injury to the tubulo-
interstitium and finally fibrosis of kidney
53
.  
A wide range of pro-inflammatory molecules are involved in the 
patho- physiological cause of Diabetic Nephropathy. 
Pro-inflammatory molecules  include : 
a) Chemokines with their receptors,  
b) Pro-inflammatory cytokines, 
c) Adhesion molecules 
d) Transcription factors. 
Inflammatory molecules in Diabetic Nephropathy:  
 
 Inflammatory cytokines  
 
            Tumor Necrosis  Factor (TNF) 
             IL-1, IL-6, IL-18.             
 Chemokines and their receptors.  
         CCL2 (MCP-1) with its receptor CCR2,  
  
          CX3CL1 (fract-alkine) with its receptor CX3CR1, 
  
          CCL5  with its receptor CCR5. 
  
 Adhesion molecules  
 
        Intercellular adhesion molecule (ICAM),  
 
        Vascular cell adhesion molecule (VCAM),  
 
Endothelial cell adhesion molecule(ECAM),  
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        E-selectin,  
          
        α-Actinin 4.  
 
 Transcription factor - Nuclear factor κB ( NFκB). 
Transcription Factor 
Nuclear Factor kappa B(NFκB),a transcription factor, forms a 
pivotal role in the process of DN.  
        Metabolic and hemodynamic pathways are the two main pathways in 
which NFκB plays a significant role in the  formation of Diabetic 
Nephropathy.  
NFκB activity is mainly perceived in tubular cells of renal cortex , in 
some glomerular cells (podocytes), which is related with the amount of 
proteinuria and the intensity of interstitial cell infiltration
54
. 
Normally, NFκB  dimers are kept in an inactive state by I kappa Bs 
(inhibitors of NF kappa B). Translocation of NFκB into the nucleus is 
prevented on binding of I kappa Bs to NFκB and the inactive state of NFκB 
is maintained in the cytoplasm.In response to extracellular signals, the 
enzyme I kappa B kinase gets activated. 
This causes degradation of I kappa Bs from NFκB and activation of 
NFκB occurs. NFκB is available in the cytoplasm, which is translocated to 
the nucleus   which in turn activate the NFκB -dependent gene expression. 
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NFκB is activated by hyperglycemia in: 
1. Endothelial cells of the vessels, 
2.  smooth muscle cells of the blood vessels, 
3. Proximal tubular epithelial  cells of the kidney 
55, 56
 
Apart from being activated  by hyperglycemia, NFκB is activated by 
 - Pro inflammatory cytokine molecules 
- Oxidant stress  
- Protein trafficking in tubular cells of the kidney 
- Angiotensin II with its receptors 
On activation, NFκB stimulates the various  number of gene 
transcription  such as chemokines(i.e; CCL2 and CCL5),nitric oxide 
synthase, cytokines, adhesion molecules. several proliferative and other 
inflammatory proteins are also included in the formation of Diabetic 
Nephropathy 
58
. 
Interestingly, NFκB activation resulting in streptozotocin-induced 
diabetes
59 
in cortical tissue of animals kidney  has been demonstrated.  
There are many evidences to show that NFκB plays a key role in 
interrelated pathways which leads to the  
i)  Structural and functional changes in the kidney, 
ii) Stimulation of the RAS, 
iii) Accumulation of glycated products, 
iv) Increased oxidative stress
57
. 
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Functions of NFκB: 
 Proliferation of cell
60
 
 Control  the cell survival 
Hence, NFκB is an integral factor in regulating many chemokines, 
inflammatory cytokines, cell adhesion proteins and other molecules which 
are responsible for the pathogenesis of Diabetic Nephropathy. 
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Vitamin D 
Vitamin D is a pro-hormone, fat soluble and was identified in the 
20th century. Vitamin D, steroid-derivative vitamin, is popularly described 
as a seco-steroid as, one of the four rings is open
60a
. Vitamin D, well 
known as “sunshine hormone”, was first recognised and framed by 
Goldblatt and Soames in 1923
61
. 
  Vitamin D, a steroid hormone, synthesised  on  exposure of skin  to 
sunlight and  is  also absorbed from foods. Vitamin D is classified as 
Vitamin D2(ergocalciferol) and vitamin D3 (cholecalciferol) .  
Cholecalciferol is synthesised naturally in the skin from 7-
dehydrocholesterol   by UV-B (290-315 nm).Diets rich in vitamin D3 are 
oily fish such as salmon, sardines, and mackerel
62
. 
Ergocalciferol is a plant derived vitamin D, produced exogenously 
by irradiation of ergosterol produced by yeast, and enters the circulation 
through diet. 
Ergocalciferol differs from cholecalciferol by a double bond and a 
methyl group on carbon 24. As both are equally potent, generally, total 
vitamin D (vitamin D3 + vitamin D2) and the metabolites are measured. 
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The vitamin D, plays a pivotal role in homeostasis of 
calcium,phosphorus & bone metabolism, and is now accepted to sub-serve 
a entire range of basic functions such as differentiation of cell , cell growth 
inhibition and modulation of immune system
63
. 
 
Synthesis of vitamin D  
  On sunlight exposure, the UV-B photons (290-315 nm) that enter the 
epidermis causes a photochemical transformation of 7-dehydrocholesterol 
(pro-vitamin D) to pre-vitamin D3. Depending on heat, pre-vitaminD3 is 
instantaneously transformed into vitamin D3 (cholecalciferol). Remaining  
UV-B rays convert pre-vitamin D3 into, tachysterol and lumisterol, which 
are biologically inactive metabolites
 64
. 
Biologically inactive vitamin D3 are carried in the blood by vitamin 
D binding proteins(DBP), α2 globulin.  Cholecalciferol, enters the 
circulation and is delivered to the liver,  there  it is transformed  to  form 
25-hydroxyvitamin D{25(OH)D } catalyzed by the cytochrome P450  
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enzymes vitamin D 25-hydroxylases  (microsomal CYP2R1 and 
mitochondrial CYP27A1), 25(OH)D  is otherwise known as calcidiol or 
calciferol, which is the inactive form, it  is the major circulating form of 
vitamin D. Calcitriol is the most relevant index to describe the human 
vitamin D status. 
In the proximal tubules of kidney, cytochrome P450 enzyme 1-α-
hydroxylase (CYP27B1) further hydroxylates 25(OH)D to 1, 25(OH)2D 
(calcitriol), which is the biologically active compound. This is followed by 
systemic transport of  1, 25(OH)2D to distal target organs, where it binds to 
a plasma membrane receptor and nuclear receptor or both of the target 
organs, resulting in the production of specific biological responses
65
.  
 24-hydroxylase (CYP24A1) is responsible to convert  25(OH)D and 
1,25(OH)2D to 24,25(OH)2D and 25(OH)D-26,23-lactone,which are the 
inactive metabolites
 66
, and through a various pathways, further they are 
converted to the calcitroic acid (1α-hydroxy-23 carboxy-24,25,26,27-
tetranorvitamin D3) which is water soluble, this undergoes urinary and 
biliary excretion
67
 . 
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The above flow chart summarises the formation of vitamin D 
metabolites 
 
Regulation of vitamin D- endocrine system 
  Major regulatory factors are 
1. 1,25(OH)2 D  inhibits the production of itself; 
2. Parathyroid hormone, enhances the formation of 1,25(OH)2D in 
kidney,   
3. serum concentrations of calcium and phosphorus
 68
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1,25(OH)2 D concentration is stringently controlled by itself,parathormone, 
calcium and phosphorus. 
1 α hydroxylase step is inhibited by increased phosphorus level and 
1,25(OH)2D directly, but inhibited by hypercalcemia indirectly, as 
hypercalcemia inhibits parathormone secretion. 25(OH)D stimulates 24 
hydroxylase, thereby diverting 25(OH)D to form inactive 24,25 (OH)2D . 
Metabolites of vitamin D  in  the circulation.                                                    
The major storage and circulating form of vitamin D  is 25(OH) D . 
It is the biologically inactive form, which is usually  measured as an record 
of vitamin D status and it does not bind to vitamin D receptor.The half-life 
of 25(OH) D is approximately 10–15 days69. The concentration of serum  
25(OH) D is usually measured   as 20–150 nmol/L or 8–60 ng/mL. 
 1,25 (OH)2 D is present in the picomolar range in the blood, about 
one thousandth that of 25(OH) D, is the biologically active form, which  
binds and acts through vitamin D receptor .The half-life of 1,25(OH) 2D is 
approximately  4–20 hours70. 
 There is a strict regulation of 1α-hydroxylation by parathormone, 
calcium, phosphate. Moreover, as its half-life, ranges between 4 – 20 
hours, the serum concentration of 1,25(OH)2D does not give an access for 
the exact measurement of total  vitamin D status. Assessment of calcitriol, 
necessitates  daily measurement, which is impractical.    
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Measurement of calcitriol is of much use in altered 1α-hydroxylation 
states, for example:  chronic kidney disease (1,25 (OH)2D  is reduced) or 
granulomatous disease (1,25(OH)2D  is increased). 
Vitamin D metabolite concentrations in serum 
71,72 
 
Vitamin D 
metabolites 
 
Concentration  of  
vitamin  D 
 
Half life 
Vitamin D 
 
0.2 – 20 ng/mL 1-2 days 
25(OH) D 50–100 nmol/L(20–40 
ng/mL) 
 
2 – 3 weeks 
24,25(OH)2 D 
 
5–12 nmol/L (2–5 ng/mL) 
 
 
1,25(OH)2 D 50–125 pmol/L (20–50 
pg/mL) 
 
4-6 hours 
 
 Vitamin D-binding Protein 
All the vitamin D metabolites are carried in the blood by means of 
carrier protein known as vitamin D-binding protein (DBP) in circulation. 
DBP is also known as group-specific component, which is a high affinity 
transport protein. DBP, with a molecular weight of 51,335 and 458 amino-
acid residues, is synthesised in liver. 
Vitamin D related molecules, i.e.,25 (OH) vitamin D bind with DBP 
as well as 24, 25(OH)2 ; comparatively more than1,25(OH)2 vitamin D
73
. 
The effect of vitamin D metabolites are regulated by DBP  in their target 
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organs. DBP concentrations are decreased in nephrotic syndrome and 
increased in pregnancy as well as in subjects on treatment with oestrogen.  
 
Molecular actions of 1, 25-dihydroxyvitamin D 
  Vitamin D and its analogues, initiate their actions via both genomic 
and non-genomic cascades.1,25(OH)2D acts occur through plasma 
membrane-initiated mechanisms  and distinct nuclear receptor-mediated.  
In the cell nucleus, 1,25(OH)2D binds with the VDR to produce 
genomic effects or in  the caveolae of the plasma membrane to produce 
non- genomic effects (rapid responses).  
These rapid responses can occur within 1–2 min to 15–45 min, but 
this  in contrast with genomic responses, generally occurs within few hours 
to days to become fully blown. 
 
Vitamin D Receptor (VDR) 
Vitamin  D intensify its actions,by binding with vitamin D receptor 
(VDR), is a member of the nuclear receptor family of ligand activated 
transcription factors. VDR was first identified by Haussler and colleagues 
in 1969
74
 and its structure was further described in 1988
75
. 
  Location of VDR gene  is on chromosome 12q13.11 and has 11 
exons. VDR is an intracellular receptor present in the nucleus. It is 
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expressed in more than 30 different human tissues and its stimulation 
accounts over 60 different genes in different cell lines.  
 
VDR is present in 
 Cardiovascular system: cardiomyocytes and smooth muscle cells 
 Endocrine system: Thyroid C-cells, Parathyroid glands,  
     Islets of Langerhans, 
 Epidermis : hair follicles, keratinocytes;  
 Gastrointestinal System: liver, stomach, esophagus, intestine,  
 Immune System: thymus, bone marrow, T and B lymphocytes,  
 Renal system: juxta-glomerular cells, ascending  Henle’s loop   
 Respiratory system:  alveolar epithelium, 
 Osteomuscular system: striated muscle, chondrocytes, osteoblasts,  
 Reproductive system: testis, uterus and ovaries; 
 Central nervous system: neurons76. 
 
Mechanism of genomic actions of 1,25(OH)2 D 
  1, 25(OH)2 D molecules penetrate the plasma membrane by DBP 
and  their genomic actions are activated by triggering the VDR. After  
binding to the VDR, it give rise to a  change in the conformation of the 
receptor and further hetero dimerization with RXR. The VDR- RXR 
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complex linked to the VDRE, which is found in the 5’ flanking region of 
target genes. 
From the surface of the VDR, the co-repressor (CoR) proteins are 
released and it allows the binding with  the co-activator (CoA) proteins. 
These molecules change the structure of chromatin then permits the 
receptor coordination with the RNA polymerase II transcriptional complex 
(POL II), resulting in the activation of   transcription of the target gene
78
. 
 
Non-genomic effects: 
Non- genomic effects begins   in the  caveolae of the plasma 
membrane. Caveolae are flask-shaped plasma membrane invaginations 
which are rich in cholesterol and sphingolipids, generally present in variety 
of cells
77
. 
 Cells having rapid response are 
 β cells of pancreas,  
 adipocytes,  
 vascular smooth muscle,  
 sertoli cells, 
 intestine, 
 monocytes and osteoblast. 
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 It involves a plasma membrane receptor and unique 1,25(OH)2D 
receptor called 1,25D-MARRS (Membrane-Associated, Rapid Response 
Steroid-binding)
79,80
. 
Non-genomic actions of 1,25 (OH)2D  stimulate the rapid translocation 
of calcium across intestinal mucosal membranes. 1,25(OH)2D binds to the 
membrane receptor  resulting in the stimulation of various second 
messenger systems, which includes phospho-lipase C, G protein-coupled 
receptors, PKC, or PI3K.  
There are several mechanisms, it includes  
a) generation of the second messengers  
b) opening of the voltage-gated chloride or calcium channels and  
Second messengers, like RAF/MAPK, may alter the cross-talk with 
the regulation  of nuclear gene expression 
81
. 
Non- genomic actions include  
i. In osteoblasts, regulation  of voltage-gated calcium and chloride 
channel  
ii. calcium entry into the skeletal muscle cell ,  
iii. myogenesis  and contractility of the skeletal muscle,  
iv. uptake of calcium by the intestinal  cells  
v. secretion of the insulin by the β cells of pancreas. 
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Biological actions of 1,25(OH)2D  
 
 
1,25 (OH)2D, through its actions on bone, kidney, small intestine and  
 
parathyroids, helps to maintain calcium and phosphate  level in blood. 
 
1) small intestine 
Vitamin D induce calcium absorption in duodenum and phosphate 
absorption in jejunum and ileum. 
a) Uptake of calcium need epithelial calcium channel CaT1 which is 
90% vitamin D dependent,   
b) calbindin- D9k which is again vitamin D-dependent, allows 
diffusion within the cell  
c)  calcium exit from the cell by Ca ATPase ( Na
+
 Ca
2+
 exchanger)
82
. 
 1, 25 (OH)2 D  aggravate the transport  of phosphate via activation of the 
Na-P1 cotransporter
83
and alters the enterocyte plasma membrane 
composition  which enhances the fluidity and phosphate uptake. 
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2) Skeleton 
It directly stimulates osteoblasts and indirectly, by releasing 
cytokines, facilitates the activation of osteoclasts. Osteoblasts has 
1,25(OH)2 D as its receptor, which expresses the (RANKL) receptor, 
activator of nuclear factor-κB  ligand. 
The receptor for RANKL is RANK, present on the preosteoclasts. 
RANK on interaction with RANKL, enhances preosteoclasts to form 
mature osteoclasts.  
Calcium and phosphorus are reabsorbed from the bone by mature 
osteoclasts, which  maintains calcium(Ca
2+
)  and phosphorus(HPO4
2−
) 
levels in the blood. The mineralization of the skeleton is enhanced by 
maintaining the adequate levels of  blood calcium and phosphorus
84
.  
1,25 (OH)2D regulates osteoclastogenesis by the reciprocal regulation of 
RANKL  and osteoproteregin(OPG). 
 
On the surface of osteoblasts, 1,25(OH)2D- VDR aggravates the 
RANKL expression. RANK binds with its receptor RANKL,resulting in 
osteoclastogenesis. On the other hand, 1,25(OH)2D-VDR complex 
attenuates the OPG expression, this OPG is a receptor that interacts with 
RANKL,  prevent RANK mediated osteoclastogenesis. 
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 1,25(OH)2 D as well as parathormone and prostaglandins stimulate 
RANKL expression
85
, but 1,25(OH)2 D  prevents OPG production with 
corresponding rise in osteoclastogenesis and activity of osteoclast.  
Thus, bone remodelling is maintained by the regulation  of  
osteoblasts and osteoclasts  
3)  kidney 
Vitamin D stimulates calcium and phosphate reabsorption. 
1,25(OH)2 D inhibits its own production in an ultra-short negative feedback 
loop. 
4) Parathyroid gland 
Vitamin D acts directly on parathyroids to attenuate  the synthesis and 
secretion of parathormone, by inhibiting transcription of parathormone 
gene and by increasing  the  calcium sensing receptor in parathyroid gland, 
sensitizing to inhibit calcium. 
5) Vitamin D is an immuomodulator, stimulates epithelial 
differentiation. 
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Non endocrine actions 
Inspite of having endocrine effects, vitamin D has autocrine, 
paracrine and intracrine actions. 
1. VDR has been located in the organs like adrenals, heart, parathyroids, 
pituitary gland, placenta, skin, ovary, mammary glands, testis, hepatocytes, 
biliary epithelial cells, thymus, pro-myelocytes, lymphocytes and colon
86
.  
2. 1α-hydroxylase is also isolated in the pancreas, skin, lymph nodes, brain, 
adrenal medulla, monocytes, macrophages and colon.These organs have  
the capacity to synthesis 1,25(OH)2 D
 87
 locally. 
Newly recognised biological actions of 1, 25(OH) 2 D are 
 More than 200 genes are controlled by 1,25(OH)2D, that includes 
genes involved in the regulation of differentiation of the cell, cellular 
proliferation, apoptosis, and angiogenesis. It reduces the 
multiplication of normal/cancer cells and stimulates their terminal 
differentiation
88
. 
 Through VDR mediated gene expression, 1,25(OH)2D induces an 
antimicrobial peptide,cathelicidin. Toll-like receptor activation of           
human macrophages de-represses the VDR expression and  25(OH) 
D-1α hydroxylase genes, resulting in the activation of the 
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cathelicidin  and  destruction of intracellular Mycobacterium 
tuberculosis
89
 
 In human, concentration of 25(OH)D and insulin secretion/action in 
target tissues are positively correlated. Deficiency of vitamin D has 
an opposite effect on the function of β cells of pancreas90. 
 VDR and 1α-hydroxylase are located in human brain favouring a 
role in central nervous system disease. 
 Life-threatening infant heart failure91 is prevented by vitamin D and 
calcium. 
 1 α,25(OH)2D has an opposite action on the Renin Angiotensin 
System and blood pressure
92
.  
 One clinical application is the therapeutic action of 1, 25(OH) 2 D 
and its active analogues in psoriasis
93
. 
 Circulating concentrations of 25(OH) D associated with  
vitamin D nutritional status
94,95,96
 
 
 
Serum 25(OH)D 
Nutritional status of 
 Vitamin D 
 
>50 nmol/L (>20 ng/mL) 
 
Sufficient 
30–50 nmol/L (12–20 ng/mL) Insufficient 
 
12–30 nmol/L (5–12 ng/mL) 
 
Deficient 
>12 nmol/L (>5 ng/mL) 
 
Severely deficient 
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 In Clinical laboratories, serum 25(OH)D  are reported by using 
international system (SI) units (nmol/L) or  conventional units (ng/mL).   
The conversion factor for converting conventional units to SI units is 
established based on the assessed value,   1 ng/mL = 2.496  nmol/L
97
. 
     Deficiency of Vitamin D increase the risk of: 
 Bipolar disease, multiple sclerosis98,  
 Type 1
99
 and 2
100
 Diabetes Mellitus, 
 Obesity, 
 Hypertension101, 
 Muscle weakness102,  
 Heart failure, cardiovascular disease103; 
 Cancers104 (breast, colorectal, prostate cancer) 
 Infectious diseases (i.e., tuberculosis
105
, seasonal epidemic influenza 
virus type A, leprosy); 
 Asthma and allergy; 
 Polycystic ovary disease, menstrual disorders and infertility; 
 Crohn's disease106 and other inflammatory bowel diseases; 
 Bone diorders (osteoporosis107,rickets, osteomalacia) 
 Periodontal disease. 
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 Rheumatoid arthritis
108
. 
Methods for detecting 25 (OH) D: 
1. Immunoassays. 
2. High Performance Liquid Chromatography (HPLC). 
3. Liquid Chromatography- Tandem Mass spectrometry (LC-
TMS). 
Methods comparison 
1. Immunoassays :  
Some of the technical aspects of ligand binding assays 
(radioimmunoassay, competitive protein binding assays) present 
with practical issues. 
 Basically difficult, because these assays operate better in a 
aqueous phase,but  25(OH) D2 and 25(OH) D3 are weakly 
soluble in water. 
 Solubility problems can be overwhelmed by manual extraction 
assays, but suffer from increased imprecision. 
 Some assays amplify vitamin D levels significantly, others 
undervalue them. 
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 More usually underestimation is noticed. This is especially 
noticed in patients on  treatment with vitamin D2, some 
immunoassays cannot detect 25(OH) D2. 
 Not able to differentiate between 25(OH) D2and 25(OH) 
D3.Thus it is tough to assess whether the patients are 
compliant with therapies or presenting with vitamin D 
malabsorption. 
2. High Performance Liquid Chromatography (HPLC)
109
: 
 
  
Technical aspects include 
 
 Overcome most of the problems of the ligand binding assays. 
 
 Necessitates a relatively large sample volume (≥ 1.0 mL ). 
 
 
2. Liquid Chromatography-Tandem Mass spectrometry 
LC-MS/MS) 
110
. 
Technical aspects of LC-MS/MS include 
 
 Precise and Accurate, due to internal standard and  its  
 
physico- chemical methods. 
 
 Gold standard method. 
 
 Uses specified concentrations of standards. 
 
 Rapid than HPLC. 
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 Distinguish  25(OH) D2and 25(OH) D3. 
 
 Requires  a smaller sample volume than HPLC (0.25 mL ). 
 
 
Role of vitamin D in type 2 DM 
 
The pathogenesis of Type 2 DM is mainly due to insulin resistance and 
altered insulin secretion by the β-cells of pancreas. Receptors of Vitamin D 
are present in the β-cells of pancreas and in the immune cells.  
1. Vitamin D is the main regulator for calcium absorption,it also 
enhances the activity of calcium-dependent endopeptidases present 
in the β-cell and stimulates the transformation of pro-insulin to 
insulin and there by  enhances the  insulin secretion by the β cells of 
pancreas.  
2. By regulating calcium pool, vitamin D stimulates the insulin action 
directly through the induction of insulin receptors expression in 
target tissues,and stimulates the intracellular processes mediated by 
insulin. 
3.  Vitamin D functions as a potent immunosuppressor. It usually  
 de-represses the various proinflammatory cytokine gene 
transcription. proinflammatory cytokines involved are IL-2, IL-12, 
and TNF-α, helps in the stimulation of regulatory T-lymphocytes, 
the synthesis of anti-inflammatory cytokines and preserves the β-
cells of pancreas from destruction.   
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In addition, Vitamin D mediates several other roles. It regulates the  
cellular proliferation, replication, differentiation, and autoimmune 
reactions, in various organs and tissues. 
 
Mechanisms of vitamin D action in Type 2 DM 
 
 
1. Effect of vitamin D on insulin secretion 
 Expression of 1,25 hydroxylase enzyme and Vitamin D receptor in 
the β-cells of pancreas indicate the  role of Vitamin D in the secretion 
of insulin. 
 Vitamin D increases the calcium concentration intracellularly through 
non-selective voltage-dependent calcium channels and thereby act 
directly to stimulate β-cell to secrete insulin  or it may enhance the 
activation of β-cell calcium-dependent endo-peptidases that converts 
pro-insulin to insulin. 
 1,25 (OH)2D is necessary for exocytosis of insulin by up-regulating 
the calbindin-D28K expression  in the β cells of pancreas112. 
 
Role of Calbindin-D28K in β cell111 
Calbindin-D28k is a protein, present predominantly in cytosol. This 
protein is a member of a family of high affinity calcium-binding proteins 
which includes S100 protein, calmodulin and parvalbumin
113
. 
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Calbindin is also found to be located in many tissues including kidney, 
bone and in tissues, such as brain and pancreas 
114
. 
 Calbindin-D28K regulates calcium levels intracellularly  in the β 
cells of pancreas, thus enhancing exocytosis of insulin, a calcium-
dependent process. 
  calbindin- D28K reduces the inflammatory cytokine-stimulated 
apoptosis of the β cells of pancreas115. 
 Calbindin-D28K attenuates calcium-mediated mitochondrial 
damage
116
, which leads to increased production of reactive oxygen 
species and subsequent apoptosis of the β cells of pancreas. Activity 
of caspase-3 is higher in islets of Langerhans of the individuals with 
Type 2 DM
117
.  
Vitamin D plays an integral role in preventing Type 2 Diabetes 
Mellitus by increasing the secretion of insulin, and overall function of the β 
cells of pancreas.  
2. Effect of vitamin D on insulin action 
 Vitamin D  acts directly, by enhancing the insulin receptor expression 
further  aggravates the responsiveness of insulin for glucose transport
118
, or 
vitamin D acts indirectly by regulating calcium extracellularly which 
controls normal influx of calcium through cell membranes and maintaining 
enough intracellular ionised calcium pool in the cytosol.  
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The role of calcium in insulin related action is of paramount 
importance. Calcium is required for the insulin regulated intracellular 
processes happening in skeletal muscle and adipose tissue, which are the 
principal target tissues for insulin.  
       Vitamin D increases the insulin receptor expression in target tissues 
and  stimulates its action for glucose transport. It also regulates the 
transcriptional activation of human insulin gene (Vitamin D Responsive 
Element [VDRE]  present in human insulin gene promoter region) . 
 
3. Effect of vitamin D on cytokines 
 
 
Low grade inflammation which occurs in DM is probably due to the 
increase in circulating cytokines such as TNFα and IL-6. When these 
inflammatory markers are significantly increased, there is  an increase in 
insulin resistance in  target tissues such as skeletal muscle and adipose 
tissue
119
.  
1. Vitamin D may improve insulin sensitivity.It also enhances the 
survival of beta cells of pancreas by causing an alteration in the 
function of cytokines.  
2. Vitamin D also binds with vitamin D response 
elements(VDRE),present in the promoter region of cytokine genes. 
This interference causes a change in the generation and even the 
action of cytokines.  
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3. Vitamin D can down regulate the NF-kB activation. NF-kB, a main 
transcription factor encoding pro-inflammatory cytokines is 
downregulated by vitamin D and thereby insulin resistance is 
decreased. 
4. Another important action of  vitamin D is the upregulation of 
calbindin which is a calcium binding protein which is present in 
many tissues especially beta cells of pancreas and hence interfering 
with the formation of cytokines.  
Due to rise in the cytosolic free calcium, calbindin can protect the 
cytokine stimulated apoptosis of the β cells of the pancreas, 
  Supplementation of vitamin D in type 2 DM patients and non-
diabetic patients with hypo-vitaminosis enhances  the secretion of insulin, 
suggested that  vitamin D aggravates the secretion  of insulin by the β cells 
of the islets of Langerhans 
120a
 and the action of the insulin in the target 
organs. 
 The supplementation of vitamin D reduces the cytokines such as IL-
6 and TNF-α resulting in decrease in insulin resistance120 and thus 
preventing DM 
Mechanisms of action of Vitamin D in Diabetic Nephropathy 
Hyperglycemia causes the intra-renal production of factors by down 
regulating VDR and 1α – hydroxylase in kidney, resulting in decrease in 
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1,25(OH)2 D re-absorption with increased levels of protein urinary 
excretion
121
.  
      The combination of hyperglycemia and the absence of VDR results 
in an intra renal increase of Renin Angiotensin System(RAS) activation, 
and simultaneously there has been suggestion that deficits in the active 
metabolite of 1,25(OH)2 D indirectly stimulate the activation of TGF -β
122
.  
In  experimental animals, 25 (OH) D has a negative effect on the 
Renin Angiotensin System, and the lower 25 (OH) vitamin D levels are 
particularly crucial in triggering Renin Angiotensin System activation and 
hyperfiltration, which are the main characteristic features of Diabetic 
Nephropathy
 123
 
Pharmacological use of vitamin D analogues to block Renin 
Angiotensin System activation exerts a therapeutic effect by increasing the 
action of   Renin Angiotensin System blockers
124
. 
The mechanisms of action of 1,25 (OH)2 D in the pathogenesis of 
proteinuria include 
1. Haemodynamic and  
2. Non -haemodynamic actions that regulate cell proliferation, 
angiogenesis, apoptosis, and anti -inflammatory action. 
1. Hemodynamic action 
  In Diabetic Nephropathy, the protective action of 1,25(OH)2 D is  
due to its negative regulatory effect on the RAS, by suppressing the 
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production of renin which is one of the mechanisms responsible for renal 
injury. 
Renin Angiotensin System plays an integral role in the maintanence 
of blood pressure, homeostasis of fluid and electrolyte
125
. Renin is a 
protease produced and secreted predominantly by the juxtaglomerular (JG) 
cells in the kidney. In human, renin is encoded by one gene. Renin 
formation is the first and rate limiting step in the Renin Angiotensin 
System. 
Cyclic AMP (cAMP) is a main intracellular signal that enhances the 
synthesis of renin in JG cells.  cAMP signals through cAMP response 
elements (CRE) present in the target gene promoters, interact with the 
members of the ATF/CREB/CREM bZIP transcription factor family which 
are in homodimeric or heterodimeric forms.  
Adenylate cyclase which are activated by membrane receptors 
converts ATP to intracellular cAMP . cAMP thus formed, interacts with 
the regulatory subunit of protein kinase A (PKA) to release the catalytic 
subunit, which enters the nucleus and phosphorylates CREM at serine 117 
or CREB at serine133. This expands the assembly of ubiquitous co-
activators CBP/p300 to promote the gene transcription
126
.Indeed, a number 
of CREs have been established in renin gene promoters that play essential 
roles in transcription of renin gene. 
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Liganded VDR binds to CREB in the presence of 1,25 (OH)2D and 
inhibits the interaction of CREB  to the CRE. This step  crucially interrupt 
the formation of CRE-CREBCBP/p300 complex. Finally this leads to 
decrease in renin gene expression
127
.  
2. Non -haemodynamic  actions: 
 1,25(OH)2D seems to inhibit myofibroblasts proliferation in 
the renal interstitium by stimulating hepatocyte growth factors, thus 
performing a protective effect on the kidneys by suppressing the activation 
of myofibroblast production in the matrix
128
.  
 
 In some experimental models, administration of 1,25(OH)2D 
decreased the loss of podocytes and inhibited their hypertrophy
129
. 
This beneficial effect is due to the direct action in signal 
modulation, by inhibiting TGF -β and bone morphogenetic protein 
(BMP -7) expression
130
. 
1,25(OH)2D and its analogues reduce proteinuria, a biomarker of kidney 
involvement. Thus, 1,25(OH)2D have  protective functions by promoting 
the reduction of proteinuria. 
In some animal models, 1,25(OH)2D and its analogues not only 
decreased the levels of proteinuria but also preserved the structure of 
glomerular podocyte apart from reducing TGF-β levels, an enhancer of 
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renal fibrosis. Apart from these, mesangial  cell proliferation
131
 which is a 
marker of renal injury is attenuated.  
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                    MATERIALS AND METHODS 
 
              The present study on the  serum 25(OH) D in patients with  
Type2 DM with and without Nephropathy is a case-control investigation, 
carried at  Diabetology Outpatient clinic in Rajiv Gandhi Government 
General Hospital, Chennai. This work was conducted after obtaining 
Institutional Ethical Committee clearance.  
The Study group included   total number of 90 known diabetics of 
more than 5 years duration,of which the control group were Type 2 DM 
patients  without nephropathy and the case group were patients with 
Diabetic Nephropathy.The control group were 45, out of which 22 were 
males  and 23 were  females, the case group were 45, out of which 24 were 
males and 21 were females. 
Inclusion criteria: 
Diabetics were diagnosed by ADA (American Diabetes Association)  
criteria 
Any one of the following is diagnostic 
 
A. Glucose 
 
 Fasting Plasma Glucose (FPG) ≥ 126mg/dL (7.0mmol/ L) (or) 
 
 Hyperglycemia symptoms and Random Plasma glucose levels        
≥200mg/dL( 11.1mmol/L) (or) 
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 2 hour Plasma glucose ≥200mg/dL( 11.1mmol/L)  
 
B. Hemoglobin A1C (HbA1C) 
 
           HbA1C   ≥6.5% 
 
 
Exclusion criteria: 
    
 Liver failure patients,  
 vitamin D deficiency patients, 
 Type 1 diabetes mellitus patients with and without   nephropathy, 
 Parathyroid disorders, 
 Patients with diabetic nephropathy with other  coexisting disease 
like obstructive uropathy, chronic glomerulonephritis 
 Patients having malabsorption syndrome, 
 Patients on drugs like barbiturates,phenytoin,Rifampicin,calcium, 
vitamin D 
 Pregnant and lactating mothers. 
 
Blood Sample collection 
 
Blood collection was done after an overnight fast for 8-12 hours. 
About 5ml  of blood was drawn from the ante-cubital vein of the study 
subjects and transferred into red topped serum tubes, from which all the 
parameters of the study were estimated.  
57 
 
The blood samples were analysed on the same day within 4 hours of 
blood collection. The biochemical parameters relevant to the study were 
analysed by the following methodologies. 
 
Urine Sample Collection 
 
 
Urine samples were collected after giving proper instructions to the patient 
 
- First voided sample was discarded 
 
- Early morning Mid-stream urine specimen was collected 
 
- Sample was collected in plastic   sterile containers. 
 
ESTIMATION OF URINE ALBUMIN CREATININE RATIO 
(UACR) 
 
 
Step 1  : Estimation of Albumin Concentration in Urine Sample 
 
Methodology : Latex Agglutination method / Immunoturbidimetry 
Kit from Biosystems Reagents & Instruments 
 
Lot number: COD 31924(1 x 50 mL) 
 
 
Principle: 
 
 Latex  particles coated   with  antihuman albumin are agglutinated  
 
by the albumin in the urine sample.  
 
 The agglutination of the latex particles is directly proportional to  
 
the concentration of the albumin in the urine and can be measured      
   
by turbidimetry. 
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Composition of reagent: 
 
 
Reagent A: Borate buffer 0.1mol/L, Sodium azide 0.95g/L,pH 10.0 
 
Reagent B: Suspesion of Latex particles coated with anti-human albumin  
 
                   antibodies,Sodium Azide 0.95g/L 
 
Albumin Standard:  50.8g/L 
 
Reagent preparation: 
 
Working reagent: Prepared the working reagent by mixing Reagent B vial 
into  Reagent A Bottle. 
 Albumin standard: Standard was reconstituted with 1ml of distilled water 
Procedure: 
 
- Working reagent and instrument were brought to 37˚c 
 
- 1mL of working reagent and 7μL of standard/sample were pipetted out 
 
- After mixing, cuvette was inserted in the instrument 
 
- Absorbance was read after 10 seconds (A1) and after 2min(A2) at 540nm. 
Calculation 
The  concentration of  the albumin in the sample was calculated using the  
formula 
Conc. of Albumin(mg/L) =    Δ A of Test       ×  Concentration of Standard                   
                                           ΔA of Standard        
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Reference interval  
 
     Urine Albumin = 3.9 to 24.4mg/day 
  
Estimation of the creatinine concentration in the urine sample 
 
Methodology : Modified Jaffe’s method 
 
 
Principle 
 
Creatinine in the sample combines with alkaline picrate to form 
creatinine picrate(orange-yellow colour). The intensity of the colour is 
directly proportional to amount of creatinine present in the sample and is 
measured spectro-photometrically at 500-520nm. 
 
Composition of reagent 
 
Reagent 1: picric acid  reagent –    picric acid – 25.8 mmol/L 
  
Reagent 2: sodium hydroxide reagent -    sodium hydroxide – 95 mmol/L 
  
  
Preparation of working reagent 
 
Working reagent was prepared by mixing equal volumes of Reagent 
1 and 2. Waited for 15 min before use. 
Standard concentration – 2.62mg/dL   which is traceable to Isotope 
Dilution Mass Spectrometry(IDMS).   
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Sample preparation 
 
Dilute urine samples with 1:10 dilution 
 
Procedure 
The analyser was first calibrated using the creatinine standard 
traceable to IDMS.100μL of diluted sample was added to 1000μL of 
working reagent. It was mixed well and fed immediately into semi-
automatic analyser. The reading obtained was multiplied by the dilution 
factor to get correct concentration of creatinine in urine sample. 
 
Calculation: 
 
Creatinine (mg/dL) =     ΔA of Test       × Concentration of Standard x dilution   
 
                                _____________                                                      factor 
                                 ΔA of Standard 
Creatinine (g/L) = Creatinine (mg/dL) / 100 
 
 
Reference interval  
 
 
 
Urine creatinine:    Adult Male = 14 to 26 mg/kg/day 
 
                             Adult Female=11 to 20mg/kg/day 
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Urine Albumin Creatinine Ratio is calculated by the following equation: 
 
                                                 
                                                     Urine Albumin (mg/L) 
                        UACR =             ____________________              
                                                   
                                                     Urine Creatinine (g/L) 
 
UACR = mg/g of Creatinine. 
Normal UACR = <30 mg of albumin/gm of creatinine, 
Microalbuminuria = 30-300 mg of albumin/gm of creatinine, 
Macroalbuminuria = > 300mg of albumin/gm of creatinine. 
 
ESTIMATION OF 25 HYDROXY VITAMIN D BY IMMUNOASSAY 
Methodology: 
    Quantitative competitive enzyme immunoassay 
    Kit from LiLo Diagnostics  
Principle: 
 25(OH)D test  is a competitive binding assay. It is a direct solid- 
 
phase Enzyme-Linked ImmunoAssay (ELISA),  
 
 Calibrators,controls and samples are directly added into a pre- 
 
designed anti 25(OH)D, highly specific, monoclonal antibody coated  
 
micro-wells. 
  
 A working solution of 200μL biotin labeled 25-OH D reagent is  
 
added into each well. 
 
 The reaction mixture is incubated for 90minutes at room 
temperature, preferably in dark. 
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 During the first incubation, a biotin-labeled 25(OH) vitamin D 
binds with the endogenous Vitamin D metabolites in the 
Calibrators, Controls and sample for a fixed number of binding 
sites on the anti-Vitamin D metabolites’ antibody.  
 
 100μL Enzyme (horseradish peroxidase) labeled streptavidin, is  
             added and interacts selectively to complexed biotin and, after    
           second wash step,100μL solution of a chromogenic substance,   
          tetramethylbenzidine (TMB) reagent, is added, then incubated at   
          room temperature for 15 minutes, resulting in  the development of    
          blue colour. 
 Development of the colour is stopped by adding 50μL 1M HCl stop 
solution. and the intensity of the colour is measured using microtitre  
plate reader at 450nm,the colour intensity developed being inversely 
proportional to the 25(OH)D concentration in the sample. 
 
 
A standard curve was obtained by plotting the absorbance versus the 
concentration of the standard. 
 
 
 
 
 
 
 
63 
 
Materials: 
 
 Standard (STD) 1-6:  
 
Human serum based buffer containing 25-hydroxyvitamin D, 0.2ml per 
standard Level. STD 1- 0 ng/mL,STD 2- 2 ng/mL, STD 3- 5 ng/mL,STD 
4- 15 ng/mL,STD 5 - 40 ng/mL, STD 6 - 80 ng/mL     
                                                                 
 Microplate - Antibody Coated Plate: 
 
A 96 well microplate (12stripsx8wells) coated with a highly specific 
antibody to (OH) vitamin D and its metabolites immobilized on the inner 
surface of the polystyrene wells.  
 
 25(OH)D biotin concentrate:  
 
A proprietary stabilizing buffer containing 25-hydroxyvitamin D labeled 
with biotin, 0.25mL in a vial. To be diluted with Sample Buffer 
 Sample - Buffer :  
 
A bottle of  22mL proprietary  Buffer reagent. 
 
 Enzyme conjugate :  
 
A bottle of 11mL proprietary stabilizing buffer containing streptavidin 
linked to horseradish peroxidase.  
 
 Controls 1 – 2 : 
 
Two vial of 0.2mL per level of control in human serum based  
 
Buffer containing25(OH)D. control 1- 10.8 ng/mL, control 2 – 64.7 ng/mL 
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   TMB Substrate :  
 
 A bottle of 11mL proprietary aqueous formulation of TMB and  hydrogen 
peroxide.  
 HCL - Stop Solution :  
 
  0.5M Hydrochloric Acid, 7 mL per kit. 
 
 Wash Buffer Concentrate:  
 
20ml Tris based buffered saline containing Tween, 20 mL per bottle. 
 
Additional materials used  
 Micro-plate reader capable of measuring absorbance at 450nm. 
  
 Precision pipettes.  
 
 Adsorbent paper 
  
 Aluminum foil 
 Distilled deionized water 
 
 
Preparation of Reagents: 
 
 100X Biotin Reagent: Reagent was mixed thoroughly before  
diluting. Prepared 1X working solution at 1:100 with Sample Buffer  
  
 20X Wash buffer: Prepared 1X Wash Buffer by adding the 
contents of the bottle(25mL) to 475 mL of distilled or deionized 
water.  
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Assay Procedure: 
 
1. 10μL of standards, controls, and patient specimens were added  into  
 
pre-designated wells.  
 
2. 200μL working solution (1x) of biotin reagent  was added into each 
well and it was mixed on a plate shaker (400 - 600rpm) for 30 
seconds.  
 
3. The plate was covered with an adhesive plate sealer. Incubated at 
room temperature (18-25
◦
C) for 90minutes. 
 
4. The contents of the wells were decanted by inverting it.  
 
250 μL of 1x Wash Solution was dispensed to all wells. This was  
 
decanted and repeated four times. To remove excess Wash Solution,  
 
inverted plate was tapped  firmly on absorbent tissue to remove  
 
excess wash solution. 
 
5. 100μL of Enzyme Conjugate reagent was added to all wells using a  
 
Micro- pipette. Then,incubated at room temperature (18-25°C)  
 
for 30 minutes. 
 
6.  Repeat  the wash step 4.  
 
7. 100μL of TMB Substrate was added  to all wells using, a micro 
pipette. Incubated at room temperature (18-25°C) for 15 to 20 
minutes.  
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8. 50μL of Stop Solution was added to all wells, in the same order the  
 
substrate  was added, using a micro pipette.  
 
9. The absorbance of each well was measured at 450 nm  using    
 
microplate reader, within 10 minutes of adding the Stop Solution 
 
 
 
Calculation of results  
A standard curve was plotted with standard concentration on x-axis  
and percentage of absorbance on y-axis. Through the standard    
points, the best fit straight line was drawn. 
The following table shows the absorbance (Optical density) of each 
standards and the concentration of 25 hydroxy vitamin D in the sample is 
obtained based on this absorbance. 
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S.NO 
 
Absorbance (Optical 
density) 
 
 
Concentration of 
Standard 
(ng/mL) 
 
 
1 0.1067 112.7 
 
 
2 0.1702 57.23 
 
 
3 0.2911 22.39 
 
 
4 0.3227 18.92 
 
 
5 0.5348 3.707 
 
 
6 0.8018 0 
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Point to point curve 
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SERUM CREATININE 
 
 
Methodology : Modified Jaffe’s method 
Principle: 
 
Creatinine in the sample undergoes chemical reaction with alkaline  picrate 
to form creatinine picrate (orange-yellow colour).The colour intensity is 
directly proportional to amount of creatinine present in the sample and is 
measured spectro-photometrically at 500-520nm. 
 
Composition of the reagent:  
 
Reagent 1: picric acid  reagent – picric acid – 25.8 mmol/L 
 
Reagent 2: sodium hydroxide  reagent - sodium hydroxide – 95 mmol/L 
 
Preparation of working reagent: 
 
Equal volume of Reagent 1 and 2 are mixed to prepare the working  
 
reagent.kept for 15 min before use. 
 
Standard concentration – 2.62mg/dl which is traceable to IDMS. 
Procedure: 
 
The analyser was first calibrated using the creatinine standard traceable to 
IDMS. 
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100μL of diluted sample was added   to  1000μL  of working reagent. It 
was mixed well and fed immediately into semi-automatic analyser.  
Calculation: 
 
Creatinine (mg/dL) =       ΔA of Test         × Concentration of Standard 
                                 ____________  
                                   ΔA of Standard 
 
 
Reference interval: 
 
Males – 0.7-1.4mg/ dL 
 
Females –   0.6-1.2mg/dl. 
 
ESTIMATED GLOMERULAR FILTRATION RATE (eGFR): 
 
 
eGFR is calculated using Serum Creatinine by Modification of Diet in  
 
Renal Disease(MDRD) formula as follows: 
 
Estimated GFR (mL/min/1.73 m
2
) = 175 × (Srcreatinine) 
-1.154
 × (Age)
-0.203 
× 
(0.742 if female)× (1.212 if African American) 
 
Sr
creatinine 
= Serum creatinine calibrated using IDMS calibrator. 
 
 
According to the National Kidney Foundation, 
 Normal GFR ranges from 90 - 120 mL/min/1.73 m
2
. 
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ESTIMATION OF SERUM GLUCOSE 
 
 
Methodology : Glucose oxidase-peroxidase method(GOD-POD),  
                         
                        endpoint method 
 
 
Principle: 
Glucose present in the sample is oxidised to yield gluconic acid and  
hydrogenperoxide in the presence of glucose oxidase.The enzyme 
peroxidase converts the oxidative coupling of 4-aminoantipyrine with 
phenol to yield a coloured quinoneimine complex with the absorbance 
proportional to the concentration of glucose in the sample.  
 
                                  Glucose oxidase 
 
Glucose + O2 + H2O   -----------------------------→      Gluconic Acid + H2O2 
 
                                                                                                                           
                                                        Peroxidase 
 
H2O2 + Phenolic compound + 4-AAP-----------------------→ Quinoneimine   dye +  
 
                                                                                                          2H2O 
 
Procedure : 
 
To 1mL of working solution,10μL of serum was added and incubated at  
 
37
◦
c for 15 mins and absorbance was measured at 505nm 
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Calculation: 
 
 
 
Glucose (mg/dl) = Absorbance of test × Conc. of  standard(100mg/dL) 
                           ___________________ 
                          Absorbance of standard 
 
 
Reference interval: 
 
Fasting glucose = 70 – 100mg/dL 
 
ESTIMATION OF SERUM CALCIUM: 
 
Methodology : Arsenazo III method, end point 
Principle :  
At neutral pH, Calcium reacts with arsenazo III, yields a blue coloured 
complex. The colour intensity is proportional to the concentration of 
calcium present in the sample. 
Procedure : 
 
To 1ml of working solution,25μL of serum was added and incubated at 
room temperature for 5 mins and absorbance was measured at 650nm. 
 
Standard concentration: 10 mg/dL 
 
 
 
 
 
73 
 
Calculation: 
 
 calcium (mg/dl) =                Absorbance of Test × Conc. Of Standard(10mg/dl) 
                                          ___________________ 
                                          Absorbance of Standard 
 
Reference interval: 
 
Serum calcium   = 8.8-10.2mg/dL 
 
ESTIMATION OF SERUM PHOSPHORUS: 
 
 
Methodology : ammonium molybdate method, end point. 
 
Principle :  
Inorganic phosphorus combines with ammonium molybdate in the 
presence of strong acids to form phosphomolybdate. The formation of 
phosphomolybdate is measured at 340 nm and is directly proportional to 
the inorganic phosphorus concentration in the sample. 
Reagent composition: ammonium molybdate, sulphuric acid, surfactant. 
Standard concentration: 5 mg/dL 
Procedure : 
 
To 1mL of working solution,20μL of serum was added and incubated at 
37
◦
C for 5 mins and absorbance was measured at 340nm. 
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Calculation: 
 
 Inorganic phosphorus (mg/dl) =    Absorbance of Test × Conc. Of Standard  
                                                  ___________________ 
                                                   Absorbance of Standard 
 
Reference interval: 
 
Serum phosphorus   = 2.5- 4.5mg/dl. 
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                              STATISTICAL  ANALYSIS 
 
1.  Data were analysed using SPSS statistical software version 16 version 
and was considered as statistically significant when the p value is less than 
0.05. 
2. Variables like BMI, serum creatinine, urine albumin creatinine ratio,  
eGFR, serum calcium, serum phosphorus, Serum 25 hydroxy vitamin D 
between cases and controls were compared by unpaired ‘t’ test. 
3. Pearson coefficient correlation was done to measure the linear 
relationship between  
    UACR and e GFR,  
    UACR and vitamin D, e GFR and vitamin D,  
    serum creatinine and 25 (OH)D,  
    Fasting glucose and  25 (OH)D,  
    Serum calcium and 25 (OH)D,  
   Serum Phosphorus and 25 (OH)D. 
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                                          RESULTS 
 
Age distribution of DN patients and controls  
In the present study, in total number of 90 patients, 45 patients with Type 2 
DM patients without nephropathy (controls) and 45 patients with diabetic 
nephropathy (cases) were investigated. The mean and standard deviation of 
the age of the cases and controls were 58.82 ±5.11 and 56.71±7.11, 
respectively. There was no statistical difference in the age between cases 
and controls (p = 0.110). Thus the study included age matched cases and 
controls as subjects. The details of age distribution among cases and 
controls were presented in table1,2 and figure 1,2. 
Gender   distribution of DN patients  and controls 
In diabetic nephropathy, Males constituted higher percentage than females. 
in control group, Females constituted higher percentage than males. There 
was no significant difference in gender among case and controls (p = 0.83). 
Thus the study included gender   matched  cases and  controls as subjects. 
The details of age distribution among cases and controls were presented in 
table 3 and figure 3. 
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Table 1.  Age   distribution   among controls  
Age Number of individuals Percentage 
 
41 – 50 years 12 26.66% 
 
51 – 60 years 17 37.77% 
 
61 – 70 years 16 33.33% 
 
>70 years 1 2.22% 
 
 
Fig 1. Age   distribution   among controls 
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Table2.Age distribution among DN patients  
 
 
Age 
 
Number of individuals 
 
Percentage 
 
 
41 – 50 years 3 6.66% 
 
51 – 60 years 28 62.22% 
 
61 – 70 years 13 28.88% 
 
>70 years 1 2.22% 
 
 
Fig 2. Age distribution among DN patients  
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Table 3.Gender distribution among the DN patients and controls 
 
 
Gender 
controls 
 
Cases 
Number of 
individuals 
percentage Number of 
individuals 
Percentage 
Male 22 49% 24 53.33% 
 
Female 23 51% 21 46.66% 
 
 
Fig 3.Gender distribution among the DN patients and controls 
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Table 4.Characteristics of patients in the study population 
Variables 
 
Control Case p value 
AGE 
 
56.71± 7.11 
 
 
58.82± 5.11 0.11 –NS 
 
 
GENDER 
MALE 
 
22(48.88%) 
 
24(53.33%) 0.83 – NS 
FEMALE  
23(51.11%) 
 
 
21(46.66%) 
HYPERTENSION 16(35%) 
 
20(44.44%) 
 
 
0.51 –NS 
SMOKING 5(11.11%) 
 
7(15.55%) 
 
 
0.75 – NS 
ALCOHOLISM 
 
4(8.88%) 
 
4(8.88%) 
 
 
1.00 – NS 
BMI 
 
27.21±  1.78 
 
28.79± 2.47 
 
 
0.01 – S 
UACR 
 
2.56± .64 
 
124.89± 67.29 
 
 
0.000- HS 
e GFR 
 
1.22 ± 7.07 
 
111.51 ± 4.32 
 
 
0.000- HS 
CREATININE .62 ± .06 
 
.68±  .08 
 
 
0.000- HS 
FASTING GLUCOSE 
 
127.78 ± 29.72 
 
188.44±  70.86 
 
 
0.000- HS 
CALCIUM 
 
9.63±  .37 9.63±  .37 
 
 
1.000- NS 
PHOSPHORUS 
 
3.04 ± .33 3.08±  .37 0.540- NS 
 
NS – NOT SIGNIFICANT if p value > 0.05 
HS – HIGHLY SIGNIFICANT if p value < 0.001 
 S   - SIGNIFICANT if p value < 0.05 
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Comparison of patient characteristics  
Table 4 compares the mean, standard deviation and p values for 
cases and controls with respect to variables like smoking, alcohol intake, 
BMI, presence of hypertension, UACR, eGFR, fasting glucose, serum 
creatinine, serum calcium, serum phosphorus. 
There was highly significant difference between cases and controls 
with respect to UACR,eGFR, fasting glucose, serum creatinine(p value 
<0.001). There was significant difference between cases and controls with 
respect to BMI(p value<0.05). While there was no significant difference 
among cases and controls with respect to smoking, alcohol intake, the 
presence of hypertension, serum calcium, serum phosphorus. 
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Table 5. Serum 25 Hydroxy vitamin D levels among DN patients and  
controls. 
 
25 
Hydroxy 
vitamin D 
Cases Controls Student 
‘t’ test 
Mean 
 
SD Mean SD  
.000 – HS 
5.6309 2.34 15.6062 3.46 
 
 
 
Fig 4. Serum 25 Hydroxy vitamin D levels in ng/mL among DN 
patients and controls (mean± SD) 
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Concentration of   serum 25 Hydroxy vitamin D levels among DN  
patients and controls 
 
The mean and standard deviation of the 25 Hydroxy vitamin D 
levels among DN patients and controls were presented in Table 5 and 
figure 4.  
The mean 25 Hydroxy vitamin D concentration in cases (patients 
with diabetic nephropathy) was 5.63± 2.34 ng/ml, while in 
controls(diabetic patients without nephropathy)  it was 15.60±3.46ng/ml. 
The difference in 25 Hydroxy vitamin D values between cases and controls 
were highly significant (p= 0.000). 
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Fig 5.Serum 25 hydroxy vitamin D levels in ng/mL among males and 
females in both the groups 
 
In fig 5, male and female distribution in both the groups were depicted. In 
our study, in Diabetic Nephropathy, 25 hydroxy vitamin D levels were 
comparatively increased in females than in males. In Type 2 Diabetes 
Mellitus, 25 hydroxy vitamin D levels were comparatively increased in 
males than in females. 
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Fig6. Comparison of BMI and 25 hydroxy vitamin D in DN  and  
in Type 2 DM 
 
This figure 6 shows the relationship between BMI and vitamin D in 
diabetic nephropathy and in Type 2 Diabetes Mellitus , there was an 
inverse relationship between BMI and vitamin D in both groups. 
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Table 6: Pearson correlation co-efficient to measure the relationship 
between UACR and e GFR 
 Cases 
 
Controls 
correlation 0.017 
 
0.229 
p value 0.912 
 
0.136 
N 45 
 
45 
 
Table 6 showed Pearson correlation co-efficient to measure the relationship 
between UACR and e GFR.  Pearson coefficient correlation was done on 
variables like UACR and eGFR in order to find the linear relationship in 
both the groups. There was weaker positive correlation between  UACR 
and e GFR in both cases & controls. 
 
Table.7 Pearson correlation co-efficient to measure the relationship 
between e GFR and vitamin D 
 Cases Controls 
 
correlation -0.145 0.103 
 
p value 0.341 0.501 
 
N 45 45 
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Table.7 showed Pearson correlation co-efficient to measure the relationship 
between e GFR and vitamin D 
Pearson coefficient correlation was done on variables like eGFR and 
vitamin D in order to find the linear relationship in both the groups. It was 
observed that,the concentration  of eGFR  increases, the concentration of 
vitamin D decreases with a weaker negative linear relationship with  
r=-0.145 in cases.  
 
Fig 7.Comparison of e GFR and 25 hydroxy vitamin D in  DN and  
in Type 2 DM  
 
 
Figure 7 showed in both diabetic nephropathy and in Type 2 Diabetes 
Mellitus, there was an inverse relationship between e GFR and 25 hydroxy 
vitamin D .Correlation was significant at the 0.01 level (2-tailed).  
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Table 8.Pearson correlation co-efficient to measure the relationship  
 
between UACR and vitamin D 
 
 Cases Controls 
 
correlation -0.115 0.060 
 
p value 0.451 0.699 
 
N 45 45 
 
 
Table 8 showed Pearson correlation co-efficient to measure the relationship 
between UACR and vitamin D 
 
Pearson coefficient correlation was done on variables like UACR 
and vitamin D in order to find the linear relationship in both the groups. It 
was observed that in cases, the concentration of UACR increases,the 
concentration of vitamin D decreases with a weaker negative linear 
relationship with r=-0.115. 
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Fig.8.Comparison of UACR and 25 hydroxy vitamin  D in DN and  
in Type 2 DM 
 
 
 
Figure 8 showed, in DN and in Type 2 DM, there was an inverse 
relationship between UACR and vitamin D,   Correlation was significant at 
the 0.01 level (2-tailed).   
In National Health And Nutrition Examination Study (NHANES) III study, 
there was a relationship between the increase in albuminuria and decrease 
in plasma 25(OH) D
132
. 
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Table.9 Pearson correlation co-efficient to measure the relationship 
between vitamin D and serum creatinine 
 
 Cases 
 
Controls 
correlation -0.029 
 
-0.029 
p value 0.851 0.849 
N 45 
 
45 
 
Table 9 showed Pearson correlation co-efficient to measure the relationship 
between vitamin D and serum creatinine 
Pearson coefficient correlation was done on variables like  vitamin D 
and serum creatinine in order to find the linear relationship in both the 
groups.  
It is observed that in cases, as the concentration of serum creatinine 
increased,the concentration of vitamin D was decreased with a weaker 
negative linear relationship with r=-0.029.  
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Figure.9.Comparison of serum creatinine and 25 hydroxy vitamin D in  DN 
and in Type 2 DM: 
 
Figure 9 showed in DN and in Type 2 DM, there was inverse relationship 
between serum creatinine and serum 25 hydroxy vitamin D 
 Correlation was significant at the 0.01 level (2-tailed). 
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Table 10.Pearson correlation co-efficient to measure the relationship  
 
between vitamin D and fasting glucose 
 
 Cases 
 
Controls 
correlation -0.022 
 
0.051 
p value 0.884 
 
0.737 
N 45 
 
45 
 
Table 10 showed Pearson correlation co-efficient to measure the 
relationship between vitamin D and fasting glucose 
 
Pearson coefficient correlation was done on variables like vitamin D 
and fasting glucose in order to find the linear relationship in both the 
groups. It was observed that in cases, as the concentration of fasting 
glucose increased,the concentration of vitamin D decreased with a weaker 
negative linear relationship with r=-0.022  
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Fig.10.Comparison of fasting glucose and 25 hydroxy vitamin D in  DN 
and in Type 2 DM: 
 
Fig.10 showed the comparison of fasting glucose and 25 hydroxy vitamin 
D in in  DN and in Type 2 DM 
Figure 10 showed in DN and in Type 2 DM, there was an inverse 
relationship between serum creatinine and serum 25 hydroxy vitamin D 
 Correlation was significant at the 0.01 level (2-tailed). 
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Table11.Pearson correlation co-efficient to measure the relationship  
 
between serum  25 hydroxy vitamin D and calcium 
 
 Cases Controls 
 
correlation -0.229 
 
-0.228 
p value 0.130 
 
0.132 
N 45 
 
45 
 
Table11 showed Pearson correlation co-efficient to measure the  
 
relationship between serum  25 hydroxy vitamin D and calcium 
 
Pearson coefficient correlation was done on variables like  vitamin D and 
serum calcium  in order to find the linear relationship in both the groups. It 
was observed that as the concentration of serum calcium increases, the 
concentration of serum vitamin D decreases with a weaker negative linear 
relationship with r= -0.229 in both cases and controls. 
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Table12.Pearson correlation co-efficient to measure the relationship 
between serum  25 hydroxy vitamin D and phosphorus 
 Cases 
 
Controls 
correlation 0.043 
 
-0.072 
p value 0.777 
 
0.640 
N 45 
 
45 
 
Table12 showed Pearson correlation co-efficient to measure the 
relationship between serum  25 hydroxy vitamin D and phosphorus 
Pearson coefficient correlation was done on variables like  vitamin D and 
serum phosphorus in order to find the linear relationship in both the 
groups. It was observed that there was weaker negative linear relationship 
with r=-0.072 in controls but weaker positive linear relationship with 
r=.043 in cases. 
 
Table 13 and 14 showed the master chart showing the details of patient 
with type 2 DM and DN which included age, gender, BMI, presence or 
absence of hypertension, smoking,alcohol,duration of diabetes, 
UACR,eGFR,serum creatinine, serum 25 hydroxy vitamin D, fasting 
glucose, serum calcium,serum phosphorus 
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Figure11. change in variables in DN and in type 2 DM 
 
 
Figure 11 showed the change in variables like BMI, fasting sugar, serum  
creatinine, e GFR, UACR, vitamin D in DN(cases) and in  
Type 2 DM without nephropathy(controls). 
 
In type 2 DM without nephropathy, the mean BMI was 27.21, in DN, the 
mean BMI was 28.79.  
In type 2 DM without nephropathy, the mean fasting sugar was 127.78, in 
DN, the mean fasting sugar was 188.44 
In type 2 DM without nephropathy, the mean serum creatinine was 0.62, in 
DN, the mean serum creatinine was 0.68 
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In type 2 DM without nephropathy, the mean e GFR was 122.91, in DN, 
the mean e GFR was 111.51.  
In type 2 DM without nephropathy, the mean UACR was 2.56 , in DN,  
the mean UACR was 124.89. 
In type 2 DM without nephropathy, the mean serum 25 hydroxy vitamin D 
was 15.6, in DN, the mean serum 25 hydroxy vitamin D was 5.63. 
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                                            Discussion  
Diabetic Nephropathy  is the  common  complication of  Diabetes 
Mellitus, which frequently leads on to ESRD, associated  with high 
mortality rate
133
. DN increases cardiovascular mortality i.e., there is a two 
to three fold increase when there is associated proteinuria
134
.  
           In the initial stages of DN, there is glomerular and tubular basement 
membrane thickening, then by hyper-filtration, albuminuria, glomerulo-
sclerosis, and tubular-interstitial fibrosis. All these structural and 
hemodynamic alterations eventually result in ESRD
135
. Microalbuminuria 
is the early marker of   Diabetic Nephropathy. 
                  The pathogenesis of DN is intricate as extracellular glucose  
acts directly on glomerular, tubular, interstitial  and vascular cells,resulting 
in the release of cytokines and growth factors, such as angiotensin II, TGF- 
β, and monocyte chemo attractant protein (MCP)-1, which all plays an 
integral role in the formation of Diabetic Nephropathy
 136
. 
RAS has been known to play a pivotal role in the progression of 
renal injury in DN.  
          These findings are demonstrated by clinical studies, on treatment 
with ACE inhibitors or Angiotensin II type1 receptor blockers can decrease 
the process of glomerulo-sclerosis, tubulo-interstitial fibrosis, and 
proteinuria
137
. 
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1,25(OH)2D is the hormonal form of vitamin D, with multiple 
physiological functions. Adequate levels of 1,25(OH)2D are necessary to 
maintain the  bone metabolism
140
, and there is also evidence that it has anti 
-proliferative effect in cellular differentiation, immune modulation and 
inhibition of the RAS
141
. 
1,25(OH)2D inhibits renin biosynthesis. Studies involving null-
mutant mice lacking the vitamin D receptor (VDR) gene develop hyper-
reninemia. The increase in renin results in  increased blood pressure and 
cardiac hypertrophy
139
. In this study, we have demonstrated that 
1,25(OH)2D functions as a negative regulator of the RAS
138
. 
The objective of this article was to summarize the scientific evidence 
relevant to the role of 25(OH) D in patients with DN and in patients with   
Type 2 DM without nephropathy. 
In this study, we have recruited 90 subjects and divided them into 
two groups. Cases(45) include DN patients, controls(45) include type 2 
DM patients without nephropathy. 
We have selected the patients after excluding the patients with liver 
failure, vitamin D deficiency, type1Diabetes Mellitus, malabsorption 
syndrome, other co-existing renal disease like chronic glomerulonephritis, 
obstructive uropathy,pregnant and lactating mothers, patients on drugs like 
barbiturates,phenytoin, rifampicin.  
100 
 
Insignificant p values were obtained for variables viz., age, gender, 
smoking, alcohol intake,and hypertension while comparing the cases and 
controls. This implied that the cases and controls were perfectly matched 
with respect to the confounding variables. 
In the present study, the mean of 25(OH) D was 5.6309±2.34 
(vitamin D deficiency)and was observed to be very much decreased in DN, 
the mean of 25(OH) D was 15.6062±3.46(vitamin D insufficiency) and 
was observed to be reduced in DM without nephropathy.  
The difference in 25(OH) D values between cases and controls were 
highly significant (p= 0.000). Similar result was also obtained by Vanessa 
A. Diaz et al
143
. 
Using t test, the mean difference for vitamin D was -9.97(95% CI, -
11.21 to - 8.73) and was statistically significant at p =0.000 as supported by 
Vanessa A. Diaz et al  
This study suggested   that   in DN, the levels of vitamin D could play a 
significant role and adequate levels of vitamin D are needed to be 
maintained to decrease the progression of Diabetic Nephropathy. 
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In the present study, correlation was done to measure the linear relationship 
between the following  variables. 
 UACR and e GFR, 
 25(OH) D and UACR, 
 25(OH) D and e GFR, 
 25(OH) D and fasting glucose, 
 25(OH) D and Serum creatinine, 
 25(OH) D and serum calcium, 
 25(OH) D and  serum phosphorus. 
The study showed 
1. UACR and e GFR 
There was a weaker positive correlation between   UACR and e GFR in 
both cases & controls, indicated that e GFR increased because of increased 
UACR. 
2. 25(OH) D and UACR 
There was  weaker negative correlation between 25(OH) D and 
UACR, indicated  that there was an inverse relationship between 
25(OH) D and UACR. 
3. 25(OH) D and e GFR 
          There   was weaker negative correlation between 25(OH) D and  
          e GFR indicated   that   there was an inverse relationship between     
102 
 
         25(OH) D   and  e GFR 
4. 25(OH) D and fasting glucose. 
         There   was weaker negative correlation between 25(OH) D and    
         fasting glucose indicated that   there was an inverse relationship   
         between 25(OH) D  and   fasting glucose. 
5. 25(OH) D and Serum creatinine. 
          There was weaker negative correlation between 25(OH) D and    
          Serum creatinine, indicated that  there was an inverse relationship    
          between 25(OH) D   and   Serum creatinine 
6. 25(OH) D and serum calcium. 
          There was weaker negative correlation between 25(OH) D and    
         Serum calcium, indicated that as the concentration of Serum calcium  
         increases,the concentration of 25(OH) D decreases. 
7. 25(OH) D and serum phosphorus 
    There was weaker negative correlation between 25(OH) D and   
    Serum phosphorus, indicated   that as the concentration of Serum   
     phosphorus   increases, the concentration of 25(OH) D decreases. 
 
              Studies establishing a benefit in supplementation of vitamin D 
to prevent the progression of renal disease suggested that this may be a 
strategy to take into consideration in future studies
144
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   These findings were supported by rat studies in which 
administration  of 1,25(OH)2D reduces the formation of glomerulosclerosis 
and the progression of proteinuria. These actions are brought  through 
parathyroid hormone-independent antiproliferative actions. There is a  
decrease in podocyte loss and podocyte hypertrophy
8
. 
According to Kim et al, oral cholecalciferol  was given as a 
treatment  for four months for patients with Type 2 DM with low blood 
levels of 25(OH)D. They found that cholecalciferol reduced albuminuria 
and urinary TGF -β1. They   concluded   that dietary 1,25(OH)2 D 
supplemented with cholecalciferol could have a effective action in 
preventing the progression of Diabetic Nephropathy
122
. 
In this study, in Type 2 DM without nephropathy, vitamin D levels 
were reduced significantly(vitamin D insufficiency)  and was negatively 
correlated with fasting glucose. 
In DN, vitamin D levels were decreased significantly (vitamin D 
deficiency) independent of the individuals age, gender and duration of 
diabetes and was negatively correlated with fasting glucose, UACR and 
eGFR.   
This showed the active role of vitamin D deficiency/vitamin D 
insufficiency in the progression of diabetes as well as its complication 
mainly Diabetic nephropathy. 
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LIMITATIONS OF THE STUDY 
 
1. The sample size is relatively small. 
2. We were able to measure only 25-OH-D and not 1,25(OH)2D in this 
study. As the half life of 1,25(OH)2D is only 4 to 6 hours and is also 
present in very small quantities we were not able to measure this 
parameter, which should have to be measured ideally. 
3.  Parathyroid hormone could have been measured to support the 
diagnosis, since it is too costly, it has not been done. 
4. We might have taken blood samples after giving vitamin D for 6 
months for the same groups to highlight  the role of vitamin D as a 
cause, but due to short duration, it has not been adopted. 
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CONCLUSION 
 
 Serum 25(OH)vitamin D is decreased in diabetic 
nephropathy(Vitamin D deficiency) and in type 2 Diabetes Mellitus 
without nephropathy patients(Vitamin D insufficiency). 
 
 The association between 25(OH)D and UACR is independent of the 
individuals age, gender and duration of diabetes. 
 
 
 When a diabetic patient progresses from Normoalbuminuria to 
Microalbuminuria, vitamin D   levels decrease significantly. 
 
 Renal impairment in diabetics is associated with significant vitamin 
D deficiency. 
 
 
 
 
 
 
106 
 
        FUTURE PROSPECTS OF THE STUDY 
 
1. A prospective cohort study may be performed to obtain vitamin D 
deficiency as a causative role in the development of nephropathy in 
Type 2 DM. 
2.  A similar study may be performed in Type 1 DM to study the role of 
vitamin D deficiency in the development of nephropathy. 
3. The role of VDR gene polymorphism in the development of   Type 2 
DM may be studied. 
4. Studies demonstrating intervention with active vitamin D seem to be 
associated with improved outcome of renal disease. 
5.  A similar study may be performed in gestational diabetes  to study the 
role of vitamin D deficiency in the development of diabetes. 
6. A study may be done to find the relationship between 25 hydroxy 
vitamin D and intact  parathormone in diabetic Nephropathy. 
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                            PROFORMA 
SAMPLE ID: 
 
NAME:                                                      HEIGHT: 
AGE:                                                                    WEIGHT: 
SEX:                                                                     BMI: 
                                                                             BP: 
 
DURATION OF DIABETES: 
 
TYPE OF TREATMENT FOR DIABETES: 
OHA □                                                                    INSULIN □ 
DRUG INTAKE: 
BARBITURATE □    PHENYTOIN □      CALCIUM □       VITAMIN D □ 
ASSOSCIATED DISEASE WITH DURATION: 
LIVER DISEASE □       RENAL DISEASE □       HYPER TENSION □                           
TYPE1 DM □              MALABSORPTION SYNDROME □ 
INVESTIGATIONS: 
1. FASTING GLUCOSE    
 
2. SERUM CREATININE 
 
3. URINE MICROALBUMIN 
 
 
Scanned by CamScanner
Scanned by CamScanner
Scanned by CamScanner
s.no age sex YRSBMI HT SMOKINGALCOHOLISMS.CREATU.ALBU.CREAUACR e GFR vit D(ng/ml)FBG Ca P
1 58 M 9 34 YES NO NO 0.8 448 2.1 217.33 109 4.89 165 9.3 2.5
2 73 M 8 29 NO NO NO 0.7 843 3.1 274.47 122 8.45 275 9.2 2.9
3 59 M 10 29 NO YES YES 0.7 796 3 269.95 115 3.76 189 10.1 3.1
4 58 M 7 28 YES NO NO 0.8 10.8 0.2 47 110 6.02 342 10.2 2.9
5 60 F 8 29 NO NO NO 0.6 58.7 0.6 99.53 111 2.67 187 9.8 2.8
6 60 M 8 27 YES NO NO 0.8 376 2.2 169.9 111 5.78 120 10.7 2.8
7 59 F 7 31 NO NO NO 0.6 221 1.9 119.69 115 7.89 154 9.8 2.7
8 63 M 10 29 YES NO NO 0.8 59.4 0.9 65.26 112 3.85 139 10.3 3.7
9 65 F 9 28 NO NO NO 0.6 11.2 0.2 62.06 111 6.97 241 9.4 3.1
10 66 M 9 31 YES NO NO 0.6 58.7 0.6 99.53 119 2.74 176 9.3 2.9
11 54 F 10 27 NO NO NO 0.6 623 4 157.32 113 3.29 214 9.3 2.8
12 54 M 10 29 YES YES YES 0.8 727 2.9 248.08 110 4.13 167 9.8 2.8
13 62 F 7 34 NO NO NO 0.6 111 1.1 102.41 112 5.85 450 9.9 3.1
14 65 M 6 31 YES NO NO 0.7 125 1.4 87.81 122 1.47 187 9.3 3.2
15 52 F 6 29 NO NO NO 0.6 91.7 0.9 104.25 106 2.89 156 9.7 2.9
16 60 F 7 27 YES NO NO 0.6 747 3.2 232.82 106 3.78 176 9.9 2.8
17 55 M 7 30 NO NO NO 0.8 364 3.4 107.09 116 5.67 271 10.3 2.8
18 65 F 7 27 YES NO NO 0.6 59.9 0.6 105.02 111 3.05 355 9.9 3.9
19 56 F 9 31 NO NO NO 0.6 125 1.4 87.81 112 9.87 129 9.2 3.8
20 66 M 8 28 YES YES YES 0.8 10.7 0.2 46.3 107 8.76 112 9.8 3.8
21 59 F 8 30 NO NO NO 0.6 138 0.7 193.94 115 7.68 234 9.4 2.9
22 58 M 9 27 YES NO NO 0.7 50.6 1.4 35.64 125 4.89 154 9.3 3.7
23 64 F 8 30 NO NO NO 0.6 642 3 213.35 111 2.54 179 9.4 2.5
24 49 M 8 27 YES YES YES 0.8 91.7 0.7 125.55 111 6.97 202 9.4 3.2
25 55 F 9 31 YES NO NO 0.6 221 1.9 119.69 110 3.12 156 9.8 3.9
26 58 F 7 28 NO NO NO 0.6 60.5 0.6 97.65 107 6.97 165 9.2 2.8
27 63 M 10 27 NO NO NO 0.8 354 2.9 122.07 110 6.87 187 9.3 2.8
28 54 F 6 30 YES NO NO 0.6 756 3 250.33 107 4.26 198 9.2 3.2
29 52 M 7 25 NO NO NO 0.8 59.2 1.2 48.15 111 1.32 126 9.7 3.2
30 58 F 8 24 NO NO NO 0.6 121 1.4 85.07 107 7.89 214 9.6 3
31 54 F 8 30 YES NO NO 0.6 68.6 0.8 90.21 115 6.87 112 9.3 2.8
32 65 M 10 33 NO NO NO 0.8 98.9 1 100.89 109 5.46 345 9.4 2.8
33 60 F 10 30 NO NO NO 0.6 123 1.5 79.55 106 7.89 167 9.4 3.9
34 62 M 9 26 NO YES NO 0.8 325 3.3 97.19 107 8.76 182 9.9 3.2
35 56 F 10 30 YES NO NO 0.6 56.8 1.3 42.36 112 9.34 194 9.2 2.9
36 50 F 9 27 NO NO NO 0.6 635 3 213.02 110 8.43 146 9.1 2.9
37 60 M 8 26 YES NO NO 0.8 59.7 0.8 72.77 106 4.56 178 9.3 2.8
38 56 M 7 28 NO NO NO 0.8 119 1.6 76.20 113 7.54 109 9.5 3.1
39 57 M 9 24 YES NO NO 0.8 350 3 117.53 108 9.29 154 9.5 3.2
40 62 M 10 28 NO YES NO 0.8 221 1.7 132.14 109 6.54 145 9.9 3.2
41 54 M 7 30 YES NO NO 0.8 54.4 1.2 46.13 109 4.56 176 9.9 2.9
42 58 M 8 33 NO NO NO 0.8 765 3.5 216.17 112 4.79 143 9.7 3.5
43 56 F 7 34 NO NO NO 0.6 654 3.5 184.84 112 3.54 110 10.3 3.5
44 67 M 8 29 YES NO NO 0.7 76.5 1.2 62.23 114 2.89 143 9.8 2.9
45 50 F 9 25 NO YES NO 0.6 321 3.4 93.55 110 8.64 156 9.8 2.8
MEAN59 NA 8 29 NA NA NA 0.7 28.8 1.8 124.89 112 5.63 188 9.63 3.09
SD 5 NA 1 2.5 NA NA NA 0.1 266 1.1 67.298 4.33 2.34 71 0.37 0.38
s.no age sex YRS BMI HT SMOKINGALCOHOLISMS.CREATU.ALB(g/L)U.CREA(mg/LUACR(g/mg of create  GFR vit D(ng/ml)FBG Ca P
1 48 M 6 26 NO YES NO 0.7 3.9 1.13 3.478 132.3 21.8 113 9.3 3.5
2 65 F 6 27 NO NO NO 0.6 6.2 2.16 2.884 115.5 13.1 174 9.2 3.2
3 49 F 7 28 YES NO NO 0.6 5.5 2.04 2.686 115.1 21 191 10.1 2.8
4 47 F 6 27 NO NO NO 0.6 3.5 1.76 1.96 111.7 11.2 145 10.2 2.9
5 55 M 7 26 YES NO NO 0.7 3 0.76 3.921 135.6 20.8 93 9.8 3
6 50 F 6 28 NO NO NO 0.6 3.7 1.96 1.878 121.8 12.4 123 10.7 3.2
7 48 M 7 28 YES NO NO 0.7 2.6 1.07 2.467 130.1 19.4 100 9.8 3.3
8 54 M 7 26 NO YES YES 0.7 3.4 0.89 3.775 136.1 11.1 179 10.3 3
9 63 F 8 30 NO NO NO 0.5 3.1 1.02 3.069 121.2 13.1 143 9.4 2.9
10 52 F 8 27 YES NO NO 0.6 3.3 1.89 1.741 113.8 12.4 98 9.3 2.9
11 59 M 10 27 NO NO NO 0.7 3.5 0.98 3.52 120.7 19.6 112 9.3 2.8
12 61 M 6 29 YES NO NO 0.7 3.2 1.38 2.29 126 22.8 156 9.8 2.8
13 68 M 7 25 NO YES NO 0.7 4.3 1.99 2.171 127.6 14.4 179 9.9 2.8
14 63 F 9 28 YES NO NO 0.6 3.9 1.97 2 109.4 16.7 163 9.3 3
15 54 F 10 27 NO NO NO 0.6 3.7 0.94 3.926 117.5 14.8 121 9.7 2.5
16 52 F 8 28 NO NO NO 0.6 3.3 1.25 2.64 109.5 11.6 99 9.9 2.7
17 67 F 8 26 NO NO NO 0.5 4.2 1.57 2.701 119.7 18.9 109 10.3 2.6
18 64 F 7 27 YES NO NO 0.6 4.6 1.98 2.303 115.8 16.8 127 9.9 2.5
19 60 M 8 29 NO NO NO 0.7 4.1 1.73 2.393 133.2 13.5 110 9.2 2.5
20 50 F 6 28 YES NO NO 0.5 3 2 1.505 127 12.5 89 9.8 3.2
21 54 M 7 30 NO NO NO 0.7 3.6 1.72 2.105 133.7 14.5 110 9.4 3.1
22 65 F 7 26 NO NO NO 0.6 3.2 1.16 2.776 115.5 21 156 9.3 2.9
23 61 M 8 30 NO YES YES 0.7 3.2 0.89 3.64 126 12.2 132 9.4 3.8
24 49 M 8 30 YES NO NO 0.7 3.4 0.83 4.096 130.6 15.9 120 9.4 3.7
25 54 F 7 28 NO NO NO 0.6 3.7 1.82 2.055 122.4 14.3 98 9.8 2.8
26 65 F 9 29 NO NO NO 0.5 3.1 1.62 1.938 120.4 19.9 133 9.2 2.8
27 72 M 9 27 NO NO NO 0.6 3.2 1.4 2.264 130.7 13.3 174 9.3 3
28 65 M 10 28 NO YES NO 0.7 3 1.67 1.766 118.3 15.7 107 9.2 3.2
29 54 F 9 28 YES NO NO 0.5 3.1 1.36 2.25 125 14.7 110 9.7 3
30 49 M 9 23 NO NO NO 0.7 2.6 1.07 2.43 123.3 11.9 90 9.6 2.8
31 45 F 8 29 NO NO NO 0.63 3.4 1.32 2.591 108.6 13.5 89 9.3 2.9
32 54 M 8 28 NO NO NO 0.69 4.1 1.5 2.760 127 12.6 171 9.4 2.9
33 67 F 7 28 YES NO NO 0.51 4.3 1.81 2.387 127.8 18.7 154 9.4 3.1
34 65 F 8 25 NO NO NO 0.54 3.1 0.98 3.184 120.4 12 132 9.9 3.2
35 62 M 7 27 YES NO NO 0.68 2.9 1.34 2.142 125.6 20.9 90 9.2 3.2
36 60 M 7 30 NO NO YES 0.67 4 1.8 2.244 128.6 19.8 123 9.1 2.9
37 54 F 8 26 YES NO NO 0.55 3.3 1.23 2.691 122.4 15.7 156 9.3 2.9
38 46 M 8 25 NO NO NO 0.72 3 1.02 2.922 124.9 15 96 9.5 3.9
39 56 F 8 29 YES NO NO 0.58 3.2 1.21 2.653 114.3 16.5 89 9.5 3.1
40 54 F 6 26 NO NO NO 0.56 2.7 0.99 2.697 119.9 13.6 110 9.9 3.7
41 65 M 6 23 YES NO YES 0.65 2.5 1.23 2.065 131 14.6 145 9.9 3.1
42 48 M 9 26 NO NO NO 0.72 3.6 1.76 2.068 123.8 11.9 132 9.7 2.8
43 52 M 10 24 NO NO NO 0.71 4 1.65 2.442 123.8 12.1 145 10.3 3.8
44 50 F 7 29 YES NO NO 0.56 2.4 1.43 1.699 121.8 21.4 166 9.8 3.2
45 57 M 8 23 NO NO NO 0.69 3.8 1.32 2.864 125.6 13.2 98 9.8 2.9

 
 
 
 
 
 
 
